US20120329796A1 - Compounds useful for treating premature aging and in particular progeria - Google Patents
Compounds useful for treating premature aging and in particular progeria Download PDFInfo
- Publication number
- US20120329796A1 US20120329796A1 US13/377,753 US201013377753A US2012329796A1 US 20120329796 A1 US20120329796 A1 US 20120329796A1 US 201013377753 A US201013377753 A US 201013377753A US 2012329796 A1 US2012329796 A1 US 2012329796A1
- Authority
- US
- United States
- Prior art keywords
- group
- amine
- quinolin
- hydrogen atom
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 281
- 206010063493 Premature ageing Diseases 0.000 title claims abstract description 111
- 208000032038 Premature aging Diseases 0.000 title claims abstract description 111
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 title description 24
- 208000007932 Progeria Diseases 0.000 title description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 372
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 215
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 201
- 125000005843 halogen group Chemical group 0.000 claims abstract description 107
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 95
- 230000001575 pathological effect Effects 0.000 claims abstract description 95
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 77
- 125000003709 fluoroalkyl group Chemical group 0.000 claims abstract description 68
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims abstract description 48
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 11
- -1 N-methylpiperazinyl group Chemical group 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 100
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 96
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- BCTMSDUZMDOITG-UHFFFAOYSA-N n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 BCTMSDUZMDOITG-UHFFFAOYSA-N 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- FXWXPPMZBPDNTC-UHFFFAOYSA-N 2-(quinolin-2-ylamino)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(NC=2N=C3C=CC=CC3=CC=2)=C1 FXWXPPMZBPDNTC-UHFFFAOYSA-N 0.000 claims description 9
- GQBMESGTPZAJPD-UHFFFAOYSA-N n-(6-methylpyridin-2-yl)quinolin-6-amine Chemical compound CC1=CC=CC(NC=2C=C3C=CC=NC3=CC=2)=N1 GQBMESGTPZAJPD-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- UWRDSNDFPLLAEN-UHFFFAOYSA-N n-[5-(trifluoromethyl)pyridin-2-yl]quinolin-6-amine Chemical compound N1=CC(C(F)(F)F)=CC=C1NC1=CC=C(N=CC=C2)C2=C1 UWRDSNDFPLLAEN-UHFFFAOYSA-N 0.000 claims description 8
- PLFPWCLLFOJLBI-UHFFFAOYSA-N 2-(quinolin-3-ylamino)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(NC=2C=C3C=CC=CC3=NC=2)=C1 PLFPWCLLFOJLBI-UHFFFAOYSA-N 0.000 claims description 7
- NZGKKWIIQVXUKY-UHFFFAOYSA-N 4-methyl-n-pyrimidin-2-ylquinolin-2-amine Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=NC=CC=N1 NZGKKWIIQVXUKY-UHFFFAOYSA-N 0.000 claims description 7
- PRWOBUDMRAPIGE-UHFFFAOYSA-N 5,8-dimethyl-n-(5-methylpyridin-2-yl)isoquinolin-6-amine Chemical compound N1=CC(C)=CC=C1NC1=CC(C)=C(C=NC=C2)C2=C1C PRWOBUDMRAPIGE-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 7
- 229940072107 ascorbate Drugs 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- CUOAGPLCYXTZFB-UHFFFAOYSA-N n-(3,5-dichloro-4-methylpyridin-2-yl)quinoxalin-2-amine Chemical compound CC1=C(Cl)C=NC(NC=2N=C3C=CC=CC3=NC=2)=C1Cl CUOAGPLCYXTZFB-UHFFFAOYSA-N 0.000 claims description 7
- LSRLBKXWOIDDGO-UHFFFAOYSA-N n-(3-methoxypyridin-2-yl)quinolin-3-amine Chemical compound COC1=CC=CN=C1NC1=CN=C(C=CC=C2)C2=C1 LSRLBKXWOIDDGO-UHFFFAOYSA-N 0.000 claims description 7
- MXQIQAXLTPMUGA-UHFFFAOYSA-N n-(3-methoxypyridin-2-yl)quinolin-6-amine Chemical compound COC1=CC=CN=C1NC1=CC=C(N=CC=C2)C2=C1 MXQIQAXLTPMUGA-UHFFFAOYSA-N 0.000 claims description 7
- JXNPYZYQNALESK-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)quinolin-3-amine Chemical compound N1=CC(C)=CC=C1NC1=CN=C(C=CC=C2)C2=C1 JXNPYZYQNALESK-UHFFFAOYSA-N 0.000 claims description 7
- VVCCKEKCVGLSKU-UHFFFAOYSA-N n-(5-nitropyridin-2-yl)quinolin-3-amine Chemical compound N1=CC([N+](=O)[O-])=CC=C1NC1=CN=C(C=CC=C2)C2=C1 VVCCKEKCVGLSKU-UHFFFAOYSA-N 0.000 claims description 7
- RCLQZXYDLVWBFO-UHFFFAOYSA-N n-(6-methylpyridin-2-yl)quinoxalin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3C=CC=CC3=NC=2)=N1 RCLQZXYDLVWBFO-UHFFFAOYSA-N 0.000 claims description 7
- JPVBCHHROCTOAY-UHFFFAOYSA-N n-[5-(trifluoromethyl)pyridin-2-yl]quinolin-3-amine Chemical compound N1=CC(C(F)(F)F)=CC=C1NC1=CN=C(C=CC=C2)C2=C1 JPVBCHHROCTOAY-UHFFFAOYSA-N 0.000 claims description 7
- DGRWWQSIXMNUFG-UHFFFAOYSA-N n-pyridin-2-ylquinoxalin-2-amine Chemical compound C=1N=C2C=CC=CC2=NC=1NC1=CC=CC=N1 DGRWWQSIXMNUFG-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229940095064 tartrate Drugs 0.000 claims description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 7
- AGJXIRGBYDQMRP-UHFFFAOYSA-N 2-(quinolin-2-ylamino)pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(NC=2N=C3C=CC=CC3=CC=2)=C1 AGJXIRGBYDQMRP-UHFFFAOYSA-N 0.000 claims description 6
- JXMJKMAWRLFXAP-UHFFFAOYSA-N 2-[(4-methylquinolin-2-yl)amino]pyridine-3-carbonitrile Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=NC=CC=C1C#N JXMJKMAWRLFXAP-UHFFFAOYSA-N 0.000 claims description 6
- YRKSELLNQXQCRF-UHFFFAOYSA-N 3-methyl-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2C(=CC3=CC=CC=C3N=2)C)=C1 YRKSELLNQXQCRF-UHFFFAOYSA-N 0.000 claims description 6
- PJKUHBGZFLHCNB-UHFFFAOYSA-N 3-methyl-n-pyridin-2-ylquinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=CC=N1 PJKUHBGZFLHCNB-UHFFFAOYSA-N 0.000 claims description 6
- JKWLLRXHEBZOLZ-UHFFFAOYSA-N 4-methoxy-n-(4-methylpyridin-2-yl)quinolin-7-amine Chemical compound C=1C=C2C(OC)=CC=NC2=CC=1NC1=CC(C)=CC=N1 JKWLLRXHEBZOLZ-UHFFFAOYSA-N 0.000 claims description 6
- GAWOGCFTXVIYQT-UHFFFAOYSA-N 4-methoxy-n-pyridin-2-ylquinolin-7-amine Chemical compound C=1C=C2C(OC)=CC=NC2=CC=1NC1=CC=CC=N1 GAWOGCFTXVIYQT-UHFFFAOYSA-N 0.000 claims description 6
- GHJMOXJEERLACS-UHFFFAOYSA-N 4-methyl-n-(5-nitropyridin-2-yl)quinolin-2-amine Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=CC=C([N+]([O-])=O)C=N1 GHJMOXJEERLACS-UHFFFAOYSA-N 0.000 claims description 6
- YGTLRZXTQCCYGE-UHFFFAOYSA-N 6-chloro-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC(Cl)=CC3=CC=2)=C1 YGTLRZXTQCCYGE-UHFFFAOYSA-N 0.000 claims description 6
- HPJXFVDJZJVWKH-UHFFFAOYSA-N 6-chloro-n-(4-methylpyridin-2-yl)quinoxalin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC(Cl)=CC3=NC=2)=C1 HPJXFVDJZJVWKH-UHFFFAOYSA-N 0.000 claims description 6
- XTHMFTROJRWDRJ-UHFFFAOYSA-N 6-chloro-n-(6-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3C=CC(Cl)=CC3=CC=2)=N1 XTHMFTROJRWDRJ-UHFFFAOYSA-N 0.000 claims description 6
- FJCJZQGLOMNRHY-UHFFFAOYSA-N 8-chloro-n-(3-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CN=C1NC1=CC=C(C=CC=C2Cl)C2=N1 FJCJZQGLOMNRHY-UHFFFAOYSA-N 0.000 claims description 6
- WUYJWZJNFJVBQS-UHFFFAOYSA-N 8-chloro-n-(3-nitropyridin-2-yl)quinolin-2-amine Chemical compound [O-][N+](=O)C1=CC=CN=C1NC1=CC=C(C=CC=C2Cl)C2=N1 WUYJWZJNFJVBQS-UHFFFAOYSA-N 0.000 claims description 6
- VVUYNQGZFMNEFR-UHFFFAOYSA-N 8-chloro-n-(5-methylpyridin-2-yl)quinolin-2-amine Chemical compound N1=CC(C)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 VVUYNQGZFMNEFR-UHFFFAOYSA-N 0.000 claims description 6
- VLWWBNACECPLGM-UHFFFAOYSA-N 8-chloro-n-[3-chloro-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 VLWWBNACECPLGM-UHFFFAOYSA-N 0.000 claims description 6
- CTJGXKWQWHICPP-UHFFFAOYSA-N 8-chloro-n-[5-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound N1=CC(C(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 CTJGXKWQWHICPP-UHFFFAOYSA-N 0.000 claims description 6
- BYMRPDIGYDXSRD-UHFFFAOYSA-N 8-chloro-n-pyrimidin-2-ylquinolin-2-amine Chemical compound N1=C2C(Cl)=CC=CC2=CC=C1NC1=NC=CC=N1 BYMRPDIGYDXSRD-UHFFFAOYSA-N 0.000 claims description 6
- FJWIHTNNFSITSP-UHFFFAOYSA-N [2-(quinoxalin-2-ylamino)pyridin-4-yl]methanol Chemical compound OCC1=CC=NC(NC=2N=C3C=CC=CC3=NC=2)=C1 FJWIHTNNFSITSP-UHFFFAOYSA-N 0.000 claims description 6
- ATZADUUVCRSIHI-UHFFFAOYSA-N n-(3-methoxypyridin-2-yl)quinolin-2-amine Chemical compound COC1=CC=CN=C1NC1=CC=C(C=CC=C2)C2=N1 ATZADUUVCRSIHI-UHFFFAOYSA-N 0.000 claims description 6
- FFUWMVQIJWHSKD-UHFFFAOYSA-N n-(3-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CN=C1NC1=CC=C(C=CC=C2)C2=N1 FFUWMVQIJWHSKD-UHFFFAOYSA-N 0.000 claims description 6
- KBXOKJZDVJGBFH-UHFFFAOYSA-N n-(3-nitropyridin-2-yl)quinolin-2-amine Chemical compound [O-][N+](=O)C1=CC=CN=C1NC1=CC=C(C=CC=C2)C2=N1 KBXOKJZDVJGBFH-UHFFFAOYSA-N 0.000 claims description 6
- XXDPXWRBTKQMSI-UHFFFAOYSA-N n-(3-nitropyridin-2-yl)quinolin-3-amine Chemical compound [O-][N+](=O)C1=CC=CN=C1NC1=CN=C(C=CC=C2)C2=C1 XXDPXWRBTKQMSI-UHFFFAOYSA-N 0.000 claims description 6
- JZVGQBIINWZGJR-UHFFFAOYSA-N n-(4,6-dimethylpyridin-2-yl)quinoxalin-2-amine Chemical compound CC1=CC(C)=NC(NC=2N=C3C=CC=CC3=NC=2)=C1 JZVGQBIINWZGJR-UHFFFAOYSA-N 0.000 claims description 6
- JNSCAEPZOZUIHU-UHFFFAOYSA-N n-(4-ethylpyridin-2-yl)quinoxalin-2-amine Chemical compound CCC1=CC=NC(NC=2N=C3C=CC=CC3=NC=2)=C1 JNSCAEPZOZUIHU-UHFFFAOYSA-N 0.000 claims description 6
- YPHGFGYLPUODNV-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)-3-(trifluoromethyl)quinoxalin-2-amine Chemical compound CC1=CC=NC(NC=2C(=NC3=CC=CC=C3N=2)C(F)(F)F)=C1 YPHGFGYLPUODNV-UHFFFAOYSA-N 0.000 claims description 6
- BSHNAVOQNSIGLC-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)quinoxalin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC=CC3=NC=2)=C1 BSHNAVOQNSIGLC-UHFFFAOYSA-N 0.000 claims description 6
- VAQHPHVXGHQBEP-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)quinolin-2-amine Chemical compound N1=CC(F)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 VAQHPHVXGHQBEP-UHFFFAOYSA-N 0.000 claims description 6
- TZRNPIATCDHHCP-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)quinolin-2-amine Chemical compound N1=CC(C)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 TZRNPIATCDHHCP-UHFFFAOYSA-N 0.000 claims description 6
- UIARFWFFSUIOQX-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)quinolin-6-amine Chemical compound N1=CC(C)=CC=C1NC1=CC=C(N=CC=C2)C2=C1 UIARFWFFSUIOQX-UHFFFAOYSA-N 0.000 claims description 6
- URFTWAYRGCNQTE-UHFFFAOYSA-N n-(5-nitropyridin-2-yl)quinolin-2-amine Chemical compound N1=CC([N+](=O)[O-])=CC=C1NC1=CC=C(C=CC=C2)C2=N1 URFTWAYRGCNQTE-UHFFFAOYSA-N 0.000 claims description 6
- PKWLZRUXTBCYEG-UHFFFAOYSA-N n-(6-methylpyridin-2-yl)quinolin-3-amine Chemical compound CC1=CC=CC(NC=2C=C3C=CC=CC3=NC=2)=N1 PKWLZRUXTBCYEG-UHFFFAOYSA-N 0.000 claims description 6
- DIHJTBLMXALNBS-UHFFFAOYSA-N n-[2-(trifluoromethoxy)phenyl]quinoxalin-2-amine Chemical compound FC(F)(F)OC1=CC=CC=C1NC1=CN=C(C=CC=C2)C2=N1 DIHJTBLMXALNBS-UHFFFAOYSA-N 0.000 claims description 6
- IJZNNUVDSNDKDH-UHFFFAOYSA-N n-[2-methyl-4-(trifluoromethoxy)phenyl]quinoxalin-2-amine Chemical compound CC1=CC(OC(F)(F)F)=CC=C1NC1=CN=C(C=CC=C2)C2=N1 IJZNNUVDSNDKDH-UHFFFAOYSA-N 0.000 claims description 6
- BXOAUNVKKPBHQR-UHFFFAOYSA-N n-[3-(trifluoromethoxy)phenyl]quinoxalin-2-amine Chemical compound FC(F)(F)OC1=CC=CC(NC=2N=C3C=CC=CC3=NC=2)=C1 BXOAUNVKKPBHQR-UHFFFAOYSA-N 0.000 claims description 6
- KYQIWVOWNUXADS-UHFFFAOYSA-N n-[4-(trifluoromethoxy)phenyl]quinoxalin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CN=C(C=CC=C2)C2=N1 KYQIWVOWNUXADS-UHFFFAOYSA-N 0.000 claims description 6
- FMVVRHSNCORERJ-UHFFFAOYSA-N n-[5-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound N1=CC(C(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 FMVVRHSNCORERJ-UHFFFAOYSA-N 0.000 claims description 6
- DJQMBIOZCUXCGM-UHFFFAOYSA-N n-[6-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC=CC(NC=2N=C3C=CC=CC3=CC=2)=N1 DJQMBIOZCUXCGM-UHFFFAOYSA-N 0.000 claims description 6
- VIOGBDYTMPSFOP-UHFFFAOYSA-N n-pyrimidin-2-ylquinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC1=NC=CC=N1 VIOGBDYTMPSFOP-UHFFFAOYSA-N 0.000 claims description 6
- KROFVRIRTYNLBH-UHFFFAOYSA-N 1-n-(8-chloroquinolin-2-yl)-4-(trifluoromethoxy)benzene-1,2-diamine Chemical compound NC1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 KROFVRIRTYNLBH-UHFFFAOYSA-N 0.000 claims description 5
- UBKNQKFAALWYST-UHFFFAOYSA-N 2-[(8-chloroquinolin-2-yl)amino]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=C(C=CC=C2Cl)C2=N1 UBKNQKFAALWYST-UHFFFAOYSA-N 0.000 claims description 5
- SXYZJVGUCCEKGQ-UHFFFAOYSA-N 2-[(8-chloroquinolin-2-yl)amino]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 SXYZJVGUCCEKGQ-UHFFFAOYSA-N 0.000 claims description 5
- CDRBXJDVDCNVCR-UHFFFAOYSA-N 2-[4-[(8-chloroquinolin-2-yl)amino]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 CDRBXJDVDCNVCR-UHFFFAOYSA-N 0.000 claims description 5
- LQYGHYLIGWZTLP-UHFFFAOYSA-N 2-n-(4-methylpyridin-2-yl)quinoline-2,8-diamine Chemical compound CC1=CC=NC(NC=2N=C3C(N)=CC=CC3=CC=2)=C1 LQYGHYLIGWZTLP-UHFFFAOYSA-N 0.000 claims description 5
- WTXUYUSDSQGBAN-UHFFFAOYSA-N 3-methyl-n-(6-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CC(NC=2C(=CC3=CC=CC=C3N=2)C)=N1 WTXUYUSDSQGBAN-UHFFFAOYSA-N 0.000 claims description 5
- KQHZIQRXEWLDJA-UHFFFAOYSA-N 4-methyl-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC=CC3=C(C)C=2)=C1 KQHZIQRXEWLDJA-UHFFFAOYSA-N 0.000 claims description 5
- HTXYLYNDCJUKPB-UHFFFAOYSA-N 4-morpholin-4-yl-n-[4-(trifluoromethoxy)phenyl]quinolin-7-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C(=CC=N2)N3CCOCC3)C2=C1 HTXYLYNDCJUKPB-UHFFFAOYSA-N 0.000 claims description 5
- YMWJCWKLKHOUSB-UHFFFAOYSA-N 4-n,4-n-dimethyl-1-n-(3-methylquinolin-2-yl)benzene-1,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1NC1=NC2=CC=CC=C2C=C1C YMWJCWKLKHOUSB-UHFFFAOYSA-N 0.000 claims description 5
- FNRTZPDQMOKWEO-UHFFFAOYSA-N 4-n,4-n-dimethyl-7-n-(4-methylpyridin-2-yl)quinoline-4,7-diamine Chemical compound C=1C=C2C(N(C)C)=CC=NC2=CC=1NC1=CC(C)=CC=N1 FNRTZPDQMOKWEO-UHFFFAOYSA-N 0.000 claims description 5
- YKAUOMYYVJQVGG-UHFFFAOYSA-N 6-(quinoxalin-2-ylamino)pyridine-3-carbonitrile Chemical compound N1=CC(C#N)=CC=C1NC1=CN=C(C=CC=C2)C2=N1 YKAUOMYYVJQVGG-UHFFFAOYSA-N 0.000 claims description 5
- VZZOWEGAADNEDX-UHFFFAOYSA-N 6-[(3-methylquinolin-2-yl)amino]pyridine-3-carbonitrile Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=C(C#N)C=N1 VZZOWEGAADNEDX-UHFFFAOYSA-N 0.000 claims description 5
- YZUSLURXWJRRKQ-UHFFFAOYSA-N 6-[(4-methylquinolin-2-yl)amino]pyridine-3-carbonitrile Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=CC=C(C#N)C=N1 YZUSLURXWJRRKQ-UHFFFAOYSA-N 0.000 claims description 5
- NQUSIBMZMQGZJP-UHFFFAOYSA-N 6-[(8-chloroquinolin-2-yl)amino]pyridine-3-carbonitrile Chemical compound N1=C2C(Cl)=CC=CC2=CC=C1NC1=CC=C(C#N)C=N1 NQUSIBMZMQGZJP-UHFFFAOYSA-N 0.000 claims description 5
- FELITWFKOKSVOU-UHFFFAOYSA-N 8-chloro-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 FELITWFKOKSVOU-UHFFFAOYSA-N 0.000 claims description 5
- ZZHVQARIQFQEHB-UHFFFAOYSA-N 8-chloro-n-(5-fluoropyridin-2-yl)quinolin-2-amine Chemical compound N1=CC(F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 ZZHVQARIQFQEHB-UHFFFAOYSA-N 0.000 claims description 5
- CGOGWGRRNFBRTN-UHFFFAOYSA-N 8-chloro-n-(6-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=N1 CGOGWGRRNFBRTN-UHFFFAOYSA-N 0.000 claims description 5
- SYIWUYCZJZKWNS-UHFFFAOYSA-N 8-chloro-n-pyridin-2-ylquinolin-2-amine Chemical compound N1=C2C(Cl)=CC=CC2=CC=C1NC1=CC=CC=N1 SYIWUYCZJZKWNS-UHFFFAOYSA-N 0.000 claims description 5
- VXECRKRPJRAULJ-UHFFFAOYSA-N n-(4-methyl-3-nitropyridin-2-yl)quinoxalin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC=CC3=NC=2)=C1[N+]([O-])=O VXECRKRPJRAULJ-UHFFFAOYSA-N 0.000 claims description 5
- FZVLZGBHFVRNLB-UHFFFAOYSA-N n-(4-methyl-5-nitropyridin-2-yl)quinoxalin-2-amine Chemical compound C1=C([N+]([O-])=O)C(C)=CC(NC=2N=C3C=CC=CC3=NC=2)=N1 FZVLZGBHFVRNLB-UHFFFAOYSA-N 0.000 claims description 5
- PTGIPIAIGZEJJI-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)-8-nitroquinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C([N+]([O-])=O)=CC=CC3=CC=2)=C1 PTGIPIAIGZEJJI-UHFFFAOYSA-N 0.000 claims description 5
- BLOLQFVGPGAZBB-UHFFFAOYSA-N n-(5-bromo-4-methylpyridin-2-yl)quinoxalin-2-amine Chemical compound C1=C(Br)C(C)=CC(NC=2N=C3C=CC=CC3=NC=2)=N1 BLOLQFVGPGAZBB-UHFFFAOYSA-N 0.000 claims description 5
- OXMZVGXPQMUGTF-UHFFFAOYSA-N n-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 OXMZVGXPQMUGTF-UHFFFAOYSA-N 0.000 claims description 5
- YQZNQAOPVNOFQW-UHFFFAOYSA-N n-pyridin-2-ylquinolin-3-amine Chemical compound C=1N=C2C=CC=CC2=CC=1NC1=CC=CC=N1 YQZNQAOPVNOFQW-UHFFFAOYSA-N 0.000 claims description 5
- BTMYCMDJXRGRLY-UHFFFAOYSA-N n-pyridin-3-ylquinolin-3-amine Chemical compound C=1N=C2C=CC=CC2=CC=1NC1=CC=CN=C1 BTMYCMDJXRGRLY-UHFFFAOYSA-N 0.000 claims description 5
- YFSKNMVMVDRGQL-UHFFFAOYSA-N 1-n-(6-chloroquinolin-2-yl)-4-n,4-n-dimethylbenzene-1,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1NC1=CC=C(C=C(Cl)C=C2)C2=N1 YFSKNMVMVDRGQL-UHFFFAOYSA-N 0.000 claims description 4
- SJQBOAPYEWHLJK-UHFFFAOYSA-N 1-n-(8-chloroquinolin-2-yl)-4-n,4-n-dimethylbenzene-1,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 SJQBOAPYEWHLJK-UHFFFAOYSA-N 0.000 claims description 4
- BKJDCCJYCUPNRL-UHFFFAOYSA-N 2-[(8-chloroquinolin-2-yl)amino]pyridin-3-ol Chemical compound OC1=CC=CN=C1NC1=CC=C(C=CC=C2Cl)C2=N1 BKJDCCJYCUPNRL-UHFFFAOYSA-N 0.000 claims description 4
- VGWOMTPTPCNRSD-UHFFFAOYSA-N 2-n-(8-chloroquinolin-2-yl)-4-methylpyridine-2,3-diamine Chemical compound CC1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1N VGWOMTPTPCNRSD-UHFFFAOYSA-N 0.000 claims description 4
- HLZQAAVXDMDYFS-UHFFFAOYSA-N 3-methyl-n-[2-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=CC=C1OC(F)(F)F HLZQAAVXDMDYFS-UHFFFAOYSA-N 0.000 claims description 4
- FQULGNZYLGGSSU-UHFFFAOYSA-N 3-methyl-n-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC(OC(F)(F)F)=CC=C1NC1=NC2=CC=CC=C2C=C1C FQULGNZYLGGSSU-UHFFFAOYSA-N 0.000 claims description 4
- VGMBGEVZRWQBOM-UHFFFAOYSA-N 3-methyl-n-[3-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=CC(OC(F)(F)F)=C1 VGMBGEVZRWQBOM-UHFFFAOYSA-N 0.000 claims description 4
- FWXKBWUMNDDJHT-UHFFFAOYSA-N 3-methyl-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=C(OC(F)(F)F)C=C1 FWXKBWUMNDDJHT-UHFFFAOYSA-N 0.000 claims description 4
- RUIHEVIZDKFBBX-UHFFFAOYSA-N 3-methyl-n-[5-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=C(C(F)(F)F)C=N1 RUIHEVIZDKFBBX-UHFFFAOYSA-N 0.000 claims description 4
- BFRIMUUKUWOPBW-UHFFFAOYSA-N 3-methyl-n-pyrazin-2-ylquinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CN=CC=N1 BFRIMUUKUWOPBW-UHFFFAOYSA-N 0.000 claims description 4
- PFFGMKJSHDWGGT-UHFFFAOYSA-N 4-methoxy-n-[4-(trifluoromethoxy)phenyl]quinolin-7-amine Chemical compound C=1C=C2C(OC)=CC=NC2=CC=1NC1=CC=C(OC(F)(F)F)C=C1 PFFGMKJSHDWGGT-UHFFFAOYSA-N 0.000 claims description 4
- BICKHJDFQUBMDX-UHFFFAOYSA-N 4-methyl-n-(6-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3C=CC=CC3=C(C)C=2)=N1 BICKHJDFQUBMDX-UHFFFAOYSA-N 0.000 claims description 4
- OCEOPRHNGQCGSQ-UHFFFAOYSA-N 4-methyl-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=CC=C(OC(F)(F)F)C=C1 OCEOPRHNGQCGSQ-UHFFFAOYSA-N 0.000 claims description 4
- WZMXBKQUZOMDOY-UHFFFAOYSA-N 4-methyl-n-pyrazin-2-ylquinolin-2-amine Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=CN=CC=N1 WZMXBKQUZOMDOY-UHFFFAOYSA-N 0.000 claims description 4
- ADHHGODRRRVYSR-UHFFFAOYSA-N 4-methyl-n-pyridin-2-ylquinolin-2-amine Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NC1=CC=CC=N1 ADHHGODRRRVYSR-UHFFFAOYSA-N 0.000 claims description 4
- OWEYRQNNNZFLKZ-UHFFFAOYSA-N 4-n,4-n-dimethyl-7-n-[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine Chemical compound C=1C=C2C(N(C)C)=CC=NC2=CC=1NC1=CC=C(OC(F)(F)F)C=C1 OWEYRQNNNZFLKZ-UHFFFAOYSA-N 0.000 claims description 4
- LHEPULDUSUAMAY-UHFFFAOYSA-N 6-(quinolin-2-ylamino)pyridine-3-carbonitrile Chemical compound N1=CC(C#N)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 LHEPULDUSUAMAY-UHFFFAOYSA-N 0.000 claims description 4
- FDBFJLXCAOZZFL-UHFFFAOYSA-N 6-chloro-n-(5-fluoropyridin-2-yl)quinolin-2-amine Chemical compound N1=CC(F)=CC=C1NC1=CC=C(C=C(Cl)C=C2)C2=N1 FDBFJLXCAOZZFL-UHFFFAOYSA-N 0.000 claims description 4
- CUQCIXHRKSXWOV-UHFFFAOYSA-N 6-chloro-n-(5-methylpyridin-2-yl)quinolin-2-amine Chemical compound N1=CC(C)=CC=C1NC1=CC=C(C=C(Cl)C=C2)C2=N1 CUQCIXHRKSXWOV-UHFFFAOYSA-N 0.000 claims description 4
- GSBHDTFVSXZRQJ-UHFFFAOYSA-N 6-chloro-n-(6-ethylpyridin-2-yl)quinolin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3C=CC(Cl)=CC3=CC=2)=N1 GSBHDTFVSXZRQJ-UHFFFAOYSA-N 0.000 claims description 4
- ABFXUMAJZGUCJM-UHFFFAOYSA-N 6-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=C(Cl)C=C2)C2=N1 ABFXUMAJZGUCJM-UHFFFAOYSA-N 0.000 claims description 4
- FOKFEEOICXUAED-UHFFFAOYSA-N 6-chloro-n-[5-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound N1=CC(C(F)(F)F)=CC=C1NC1=CC=C(C=C(Cl)C=C2)C2=N1 FOKFEEOICXUAED-UHFFFAOYSA-N 0.000 claims description 4
- ZUSBYXKHPAAGKP-UHFFFAOYSA-N 6-chloro-n-pyrazin-2-ylquinolin-2-amine Chemical compound C1=CC2=CC(Cl)=CC=C2N=C1NC1=CN=CC=N1 ZUSBYXKHPAAGKP-UHFFFAOYSA-N 0.000 claims description 4
- KLDBYFPTUGYQSF-UHFFFAOYSA-N 8-bromo-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C(Br)=CC=CC3=CC=2)=C1 KLDBYFPTUGYQSF-UHFFFAOYSA-N 0.000 claims description 4
- MLMZDTAOJFGGJT-UHFFFAOYSA-N 8-bromo-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Br)C2=N1 MLMZDTAOJFGGJT-UHFFFAOYSA-N 0.000 claims description 4
- IYLUIBBHBDWNTE-UHFFFAOYSA-N 8-bromo-n-pyrazin-2-ylquinolin-2-amine Chemical compound N1=C2C(Br)=CC=CC2=CC=C1NC1=CN=CC=N1 IYLUIBBHBDWNTE-UHFFFAOYSA-N 0.000 claims description 4
- RUURRABBFPPQTD-UHFFFAOYSA-N 8-chloro-n-(3-chloro-4-methoxyphenyl)quinolin-2-amine Chemical compound C1=C(Cl)C(OC)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 RUURRABBFPPQTD-UHFFFAOYSA-N 0.000 claims description 4
- VXBYNYBZMRMLGW-UHFFFAOYSA-N 8-chloro-n-(3-ethyl-6-methylpyridin-2-yl)quinolin-2-amine Chemical compound CCC1=CC=C(C)N=C1NC1=CC=C(C=CC=C2Cl)C2=N1 VXBYNYBZMRMLGW-UHFFFAOYSA-N 0.000 claims description 4
- UKMWIGDFVUOYBF-UHFFFAOYSA-N 8-chloro-n-(3-fluorophenyl)quinolin-2-amine Chemical compound FC1=CC=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 UKMWIGDFVUOYBF-UHFFFAOYSA-N 0.000 claims description 4
- FPOCSJDULFADOD-UHFFFAOYSA-N 8-chloro-n-(4,6-dimethylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC(C)=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 FPOCSJDULFADOD-UHFFFAOYSA-N 0.000 claims description 4
- SVMQCHZHOIOPBT-UHFFFAOYSA-N 8-chloro-n-(4-chloropyridin-2-yl)quinolin-2-amine Chemical compound ClC1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 SVMQCHZHOIOPBT-UHFFFAOYSA-N 0.000 claims description 4
- QIIKTTKZMMJAOF-UHFFFAOYSA-N 8-chloro-n-(4-ethylpyridin-2-yl)quinolin-2-amine Chemical compound CCC1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 QIIKTTKZMMJAOF-UHFFFAOYSA-N 0.000 claims description 4
- ONRLMLQEVUKZKC-UHFFFAOYSA-N 8-chloro-n-(4-methoxyphenyl)quinolin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 ONRLMLQEVUKZKC-UHFFFAOYSA-N 0.000 claims description 4
- YVQAPMHRGKJEHA-UHFFFAOYSA-N 8-chloro-n-(6-ethylpyridin-2-yl)quinolin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=N1 YVQAPMHRGKJEHA-UHFFFAOYSA-N 0.000 claims description 4
- QQHGKWJGEQGJGO-UHFFFAOYSA-N 8-chloro-n-[3-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound FC(F)(F)OC1=CC=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 QQHGKWJGEQGJGO-UHFFFAOYSA-N 0.000 claims description 4
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 claims description 4
- ZYUBUXKVZUJXAK-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 ZYUBUXKVZUJXAK-UHFFFAOYSA-N 0.000 claims description 4
- ZCIMXMMWBLMIKS-UHFFFAOYSA-N 8-chloro-n-[6-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=N1 ZCIMXMMWBLMIKS-UHFFFAOYSA-N 0.000 claims description 4
- WIZXEYUXFXEMET-UHFFFAOYSA-N 8-chloro-n-pyrazin-2-ylquinolin-2-amine Chemical compound N1=C2C(Cl)=CC=CC2=CC=C1NC1=CN=CC=N1 WIZXEYUXFXEMET-UHFFFAOYSA-N 0.000 claims description 4
- TVDAFLMOGGSQRO-UHFFFAOYSA-N 8-chloro-n-pyridin-4-ylquinolin-2-amine Chemical compound N1=C2C(Cl)=CC=CC2=CC=C1NC1=CC=NC=C1 TVDAFLMOGGSQRO-UHFFFAOYSA-N 0.000 claims description 4
- AZUPXAKEVZEVGM-UHFFFAOYSA-N 8-fluoro-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C(F)=CC=CC3=CC=2)=C1 AZUPXAKEVZEVGM-UHFFFAOYSA-N 0.000 claims description 4
- JKCVPDYTKRGXRQ-UHFFFAOYSA-N 8-fluoro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound N1=C2C(F)=CC=CC2=CC=C1NC1=CC=C(OC(F)(F)F)C=C1 JKCVPDYTKRGXRQ-UHFFFAOYSA-N 0.000 claims description 4
- XQNWJAZOZPLABG-UHFFFAOYSA-N 8-fluoro-n-pyrazin-2-ylquinolin-2-amine Chemical compound N1=C2C(F)=CC=CC2=CC=C1NC1=CN=CC=N1 XQNWJAZOZPLABG-UHFFFAOYSA-N 0.000 claims description 4
- TZUPDIOVNPBGBH-UHFFFAOYSA-N 8-methoxy-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound N1=C2C(OC)=CC=CC2=CC=C1NC1=CC(C)=CC=N1 TZUPDIOVNPBGBH-UHFFFAOYSA-N 0.000 claims description 4
- AHEAPCRPIGIXST-UHFFFAOYSA-N 8-methoxy-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound N1=C2C(OC)=CC=CC2=CC=C1NC1=CC=C(OC(F)(F)F)C=C1 AHEAPCRPIGIXST-UHFFFAOYSA-N 0.000 claims description 4
- MRNHPXYSBYGPDT-UHFFFAOYSA-N 8-methoxy-n-pyrazin-2-ylquinolin-2-amine Chemical compound N1=C2C(OC)=CC=CC2=CC=C1NC1=CN=CC=N1 MRNHPXYSBYGPDT-UHFFFAOYSA-N 0.000 claims description 4
- JIJMLBPEQULHTQ-UHFFFAOYSA-N 8-methyl-n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C(C)=CC=CC3=CC=2)=C1 JIJMLBPEQULHTQ-UHFFFAOYSA-N 0.000 claims description 4
- PAZITGANORKJQX-UHFFFAOYSA-N 8-methyl-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound N1=C2C(C)=CC=CC2=CC=C1NC1=CC=C(OC(F)(F)F)C=C1 PAZITGANORKJQX-UHFFFAOYSA-N 0.000 claims description 4
- DUVUANQFUWEQTA-UHFFFAOYSA-N 8-methyl-n-pyrazin-2-ylquinolin-2-amine Chemical compound N1=C2C(C)=CC=CC2=CC=C1NC1=CN=CC=N1 DUVUANQFUWEQTA-UHFFFAOYSA-N 0.000 claims description 4
- REHMWTOCBIBVLH-UHFFFAOYSA-N methyl 2-[(8-chloroquinolin-2-yl)amino]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1NC1=CC=C(C=CC=C2Cl)C2=N1 REHMWTOCBIBVLH-UHFFFAOYSA-N 0.000 claims description 4
- RNMAOVZACIEZRY-UHFFFAOYSA-N methyl 6-(quinolin-2-ylamino)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 RNMAOVZACIEZRY-UHFFFAOYSA-N 0.000 claims description 4
- XAEVJVCCEZTOPK-UHFFFAOYSA-N methyl 6-[(3-methylquinolin-2-yl)amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC1=NC2=CC=CC=C2C=C1C XAEVJVCCEZTOPK-UHFFFAOYSA-N 0.000 claims description 4
- OZHCMCMAYBRCAZ-UHFFFAOYSA-N methyl 6-[(4-methylquinolin-2-yl)amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC1=CC(C)=C(C=CC=C2)C2=N1 OZHCMCMAYBRCAZ-UHFFFAOYSA-N 0.000 claims description 4
- RHSWLGNBNIMYDD-UHFFFAOYSA-N methyl 6-[(8-chloroquinolin-2-yl)amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 RHSWLGNBNIMYDD-UHFFFAOYSA-N 0.000 claims description 4
- JSKBVMQTOGGRCE-UHFFFAOYSA-N n-(3-fluorophenyl)quinolin-2-amine Chemical compound FC1=CC=CC(NC=2N=C3C=CC=CC3=CC=2)=C1 JSKBVMQTOGGRCE-UHFFFAOYSA-N 0.000 claims description 4
- RXKPLHQYESBUJR-UHFFFAOYSA-N n-(4-butoxyphenyl)-3-methylquinolin-2-amine Chemical compound C1=CC(OCCCC)=CC=C1NC1=NC2=CC=CC=C2C=C1C RXKPLHQYESBUJR-UHFFFAOYSA-N 0.000 claims description 4
- QKBLJZFNGUXODV-UHFFFAOYSA-N n-(4-butoxyphenyl)-8-chloroquinolin-2-amine Chemical compound C1=CC(OCCCC)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 QKBLJZFNGUXODV-UHFFFAOYSA-N 0.000 claims description 4
- DAURSXXYUVTURL-UHFFFAOYSA-N n-(4-methoxyphenyl)-3-methylquinolin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC2=CC=CC=C2C=C1C DAURSXXYUVTURL-UHFFFAOYSA-N 0.000 claims description 4
- XZVNMJHAARVTEN-UHFFFAOYSA-N n-(4-methoxyphenyl)-4-(4-methylpiperazin-1-yl)quinolin-7-amine Chemical compound C1=CC(OC)=CC=C1NC1=CC=C(C(=CC=N2)N3CCN(C)CC3)C2=C1 XZVNMJHAARVTEN-UHFFFAOYSA-N 0.000 claims description 4
- GQACZYQLUYMKPJ-UHFFFAOYSA-N n-(4-methoxyphenyl)quinolin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 GQACZYQLUYMKPJ-UHFFFAOYSA-N 0.000 claims description 4
- GSPMGXUDYBBILM-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)-4-morpholin-4-ylquinolin-7-amine Chemical compound CC1=CC=NC(NC=2C=C3N=CC=C(C3=CC=2)N2CCOCC2)=C1 GSPMGXUDYBBILM-UHFFFAOYSA-N 0.000 claims description 4
- RHJPSLQTVHULQZ-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)-5-nitroquinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC=C(C3=CC=2)[N+]([O-])=O)=C1 RHJPSLQTVHULQZ-UHFFFAOYSA-N 0.000 claims description 4
- HMSBPHQTMVDQHH-UHFFFAOYSA-N n-(4-nitrophenyl)quinolin-2-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=CC=C(C=CC=C2)C2=N1 HMSBPHQTMVDQHH-UHFFFAOYSA-N 0.000 claims description 4
- DFNDJRRFQJXVJE-UHFFFAOYSA-N n-(4-phenoxyphenyl)quinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 DFNDJRRFQJXVJE-UHFFFAOYSA-N 0.000 claims description 4
- OMAQEXWZVZKBCZ-UHFFFAOYSA-N n-(5-bromo-4-methylpyridin-2-yl)-8-chloroquinolin-2-amine Chemical compound C1=C(Br)C(C)=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=N1 OMAQEXWZVZKBCZ-UHFFFAOYSA-N 0.000 claims description 4
- KSLQIQYOOVWDEP-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-3-methylquinolin-2-amine Chemical compound CC1=CC2=CC=CC=C2N=C1NC1=CC=C(F)C=N1 KSLQIQYOOVWDEP-UHFFFAOYSA-N 0.000 claims description 4
- VSXGLAGXFHRXQM-UHFFFAOYSA-N n-(6-ethylpyridin-2-yl)-3-methylquinolin-2-amine Chemical compound CCC1=CC=CC(NC=2C(=CC3=CC=CC=C3N=2)C)=N1 VSXGLAGXFHRXQM-UHFFFAOYSA-N 0.000 claims description 4
- NOFXAEONSDUIOM-UHFFFAOYSA-N n-[2-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound FC(F)(F)OC1=CC=CC=C1NC1=CC=C(C=CC=C2)C2=N1 NOFXAEONSDUIOM-UHFFFAOYSA-N 0.000 claims description 4
- NVOIOZMCFMHTMV-UHFFFAOYSA-N n-[3-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound FC(F)(F)OC1=CC=CC(NC=2N=C3C=CC=CC3=CC=2)=C1 NVOIOZMCFMHTMV-UHFFFAOYSA-N 0.000 claims description 4
- IFKURQMAQPEGBY-UHFFFAOYSA-N n-[4-(trifluoromethoxy)phenyl]quinolin-3-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CN=C(C=CC=C2)C2=C1 IFKURQMAQPEGBY-UHFFFAOYSA-N 0.000 claims description 4
- UQECIBDLOFNABS-UHFFFAOYSA-N n-pyrazin-2-ylquinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC1=CN=CC=N1 UQECIBDLOFNABS-UHFFFAOYSA-N 0.000 claims description 4
- UFMKHVYZRJLHMM-UHFFFAOYSA-N n-pyrazin-2-ylquinolin-3-amine Chemical compound C=1N=C2C=CC=CC2=CC=1NC1=CN=CC=N1 UFMKHVYZRJLHMM-UHFFFAOYSA-N 0.000 claims description 4
- NRBSSBDWCJDZTE-UHFFFAOYSA-N n-pyrazin-2-ylquinolin-6-amine Chemical compound C=1C=C2N=CC=CC2=CC=1NC1=CN=CC=N1 NRBSSBDWCJDZTE-UHFFFAOYSA-N 0.000 claims description 4
- PZGCDTSZRXPXBJ-UHFFFAOYSA-N n-pyridin-4-ylquinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC1=CC=NC=C1 PZGCDTSZRXPXBJ-UHFFFAOYSA-N 0.000 claims description 4
- YYFITUYWFOTKBO-UHFFFAOYSA-N n-pyridin-4-ylquinolin-3-amine Chemical compound C=1N=C2C=CC=CC2=CC=1NC1=CC=NC=C1 YYFITUYWFOTKBO-UHFFFAOYSA-N 0.000 claims description 4
- QDEITQFFEKGMCH-UHFFFAOYSA-N n-pyrimidin-2-ylquinoxalin-2-amine Chemical compound C=1N=C2C=CC=CC2=NC=1NC1=NC=CC=N1 QDEITQFFEKGMCH-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- YFKLMAPHIMPQJI-UHFFFAOYSA-N 2-n-(4-methylpyridin-2-yl)quinoline-2,5-diamine Chemical compound CC1=CC=NC(NC=2N=C3C=CC=C(N)C3=CC=2)=C1 YFKLMAPHIMPQJI-UHFFFAOYSA-N 0.000 claims description 3
- RZGVHAHGCJOOLM-UHFFFAOYSA-N 3-methyl-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine;hydrochloride Chemical compound [Cl-].CC1=CC2=CC=CC=C2[NH+]=C1NC1=CC=C(OC(F)(F)F)C=C1 RZGVHAHGCJOOLM-UHFFFAOYSA-N 0.000 claims description 3
- LFODQFOSXSMJRS-UHFFFAOYSA-N 4-methyl-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine;hydrochloride Chemical compound [Cl-].[NH+]=1C2=CC=CC=C2C(C)=CC=1NC1=CC=C(OC(F)(F)F)C=C1 LFODQFOSXSMJRS-UHFFFAOYSA-N 0.000 claims description 3
- YTYBSSXNNMYTMP-UHFFFAOYSA-N 6-(quinolin-2-ylamino)pyridine-3-carbonitrile;hydrochloride Chemical compound [Cl-].[NH+]1=CC(C#N)=CC=C1NC1=CC=C(C=CC=C2)C2=N1 YTYBSSXNNMYTMP-UHFFFAOYSA-N 0.000 claims description 3
- HYQKEYKCHFZSNV-UHFFFAOYSA-N 6-[(8-chloroquinolin-2-yl)amino]-2-methylpyridine-3-carbonitrile Chemical compound C1=C(C#N)C(C)=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 HYQKEYKCHFZSNV-UHFFFAOYSA-N 0.000 claims description 3
- ZRNNTAQMCOKIDY-UHFFFAOYSA-N 6-methyl-n-naphthalen-2-ylpyridin-2-amine Chemical compound CC1=CC=CC(NC=2C=C3C=CC=CC3=CC=2)=N1 ZRNNTAQMCOKIDY-UHFFFAOYSA-N 0.000 claims description 3
- VGRDQPQJPXXCSR-UHFFFAOYSA-N 8-chloro-n-(4-methylpyridin-2-yl)quinolin-2-amine;hydrochloride Chemical compound [Cl-].CC1=CC=[NH+]C(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 VGRDQPQJPXXCSR-UHFFFAOYSA-N 0.000 claims description 3
- DMGALOCEQNYOHP-UHFFFAOYSA-N 8-chloro-n-[2-methyl-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CC1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 DMGALOCEQNYOHP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- GSRHJQVZZBVVNF-UHFFFAOYSA-N n-(4-methoxyphenyl)quinolin-3-amine Chemical compound C1=CC(OC)=CC=C1NC1=CN=C(C=CC=C2)C2=C1 GSRHJQVZZBVVNF-UHFFFAOYSA-N 0.000 claims description 3
- ZTKSVFASFFNDNT-UHFFFAOYSA-N n-(6-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3C=CC=CC3=CC=2)=N1 ZTKSVFASFFNDNT-UHFFFAOYSA-N 0.000 claims description 3
- IPGFXJBAOMYECZ-UHFFFAOYSA-N n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine;hydrochloride Chemical compound [Cl-].C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2)C2=[NH+]1 IPGFXJBAOMYECZ-UHFFFAOYSA-N 0.000 claims description 3
- BEEMTSFIVSXCQT-UHFFFAOYSA-N n-naphthalen-2-ylpyridin-2-amine Chemical compound C=1C=C2C=CC=CC2=CC=1NC1=CC=CC=N1 BEEMTSFIVSXCQT-UHFFFAOYSA-N 0.000 claims description 2
- 229940125268 obefazimod Drugs 0.000 claims description 2
- QIXQMUJFJFOLSP-UHFFFAOYSA-N N1=C(C=CC=C1)C1=CC(=NC2=CC=CC=C12)N.CC1=CC(=NC=C1)NC1=NC2=CC=CC=C2C=C1 Chemical compound N1=C(C=CC=C1)C1=CC(=NC2=CC=CC=C12)N.CC1=CC(=NC=C1)NC1=NC2=CC=CC=C2C=C1 QIXQMUJFJFOLSP-UHFFFAOYSA-N 0.000 claims 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 150000004701 malic acid derivatives Chemical class 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 91
- 125000003373 pyrazinyl group Chemical group 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 248
- 238000005160 1H NMR spectroscopy Methods 0.000 description 129
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 63
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 54
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 48
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 46
- 239000000203 mixture Substances 0.000 description 30
- 0 [3*]C1=CC=C(NC2=[Y]C3=CC=CC=C3C=C2)C=C1[4*] Chemical compound [3*]C1=CC=C(NC2=[Y]C3=CC=CC=C3C=C2)C=C1[4*] 0.000 description 26
- 229910000024 caesium carbonate Inorganic materials 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 23
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 16
- 102100026531 Prelamin-A/C Human genes 0.000 description 16
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 15
- 230000035772 mutation Effects 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 108020005067 RNA Splice Sites Proteins 0.000 description 10
- 230000001594 aberrant effect Effects 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- XIIBKSUYPNYSQZ-UHFFFAOYSA-N CC.CN(C1=NC2=CC=CC=C2C=C1)C1=NC=CC=N1.C[Rn] Chemical compound CC.CN(C1=NC2=CC=CC=C2C=C1)C1=NC=CC=N1.C[Rn] XIIBKSUYPNYSQZ-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- KDESMWOFJIQDRA-UHFFFAOYSA-N CC.CN(C1=CC2=CC=CC=C2N=C1)C1=NC=CC=C1.C[Rn] Chemical compound CC.CN(C1=CC2=CC=CC=C2N=C1)C1=NC=CC=C1.C[Rn] KDESMWOFJIQDRA-UHFFFAOYSA-N 0.000 description 6
- JSNBKJDQBGHCJL-UHFFFAOYSA-N CC.CN(C1=NC=CC=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] Chemical compound CC.CN(C1=NC=CC=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] JSNBKJDQBGHCJL-UHFFFAOYSA-N 0.000 description 6
- SNECWTJEZHRCGO-UHFFFAOYSA-N CC.CN(C1=NC=CC=C1)C1=NC2=CC=CC=C2N=C1.C[Rn] Chemical compound CC.CN(C1=NC=CC=C1)C1=NC2=CC=CC=C2N=C1.C[Rn] SNECWTJEZHRCGO-UHFFFAOYSA-N 0.000 description 6
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- AULLPZPGEQAVPO-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C=CC=CC3=CC=2)=C1 AULLPZPGEQAVPO-UHFFFAOYSA-N 0.000 description 6
- BYHVGQHIAFURIL-UHFFFAOYSA-N 2-chloroquinoxaline Chemical compound C1=CC=CC2=NC(Cl)=CN=C21 BYHVGQHIAFURIL-UHFFFAOYSA-N 0.000 description 5
- JLBICFHLGIEXHA-UHFFFAOYSA-N CC.CN(C1=CC2=CC=CN=C2C=C1)C1=NC=CC=C1.C[Rn] Chemical compound CC.CN(C1=CC2=CC=CN=C2C=C1)C1=NC=CC=C1.C[Rn] JLBICFHLGIEXHA-UHFFFAOYSA-N 0.000 description 5
- JQIFQDFHDZXGPP-UHFFFAOYSA-N CC.CN(C1=NC2=CC=CC=C2N=C1)C1=NC=CC=N1.C[Rn] Chemical compound CC.CN(C1=NC2=CC=CC=C2N=C1)C1=NC=CC=N1.C[Rn] JQIFQDFHDZXGPP-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 229940049920 malate Drugs 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- KCOXRRBWNLLKJS-UHFFFAOYSA-N CC.CN(C1=CC=CC=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] Chemical compound CC.CN(C1=CC=CC=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] KCOXRRBWNLLKJS-UHFFFAOYSA-N 0.000 description 4
- SDZWIYIDKLEJHB-UHFFFAOYSA-N CC.CN(C1=NC=CN=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] Chemical compound CC.CN(C1=NC=CN=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] SDZWIYIDKLEJHB-UHFFFAOYSA-N 0.000 description 4
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 108010021099 Lamin Type A Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- LKKVSUQIZFOEEK-UHFFFAOYSA-N n-pyridin-2-ylquinolin-2-amine Chemical compound C=1C=C2C=CC=CC2=NC=1NC1=CC=CC=N1 LKKVSUQIZFOEEK-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003586 protic polar solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical class NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
- MJPWEOSCYPTWIC-UHFFFAOYSA-N 7-chloro-4-methoxyquinoline Chemical compound ClC1=CC=C2C(OC)=CC=NC2=C1 MJPWEOSCYPTWIC-UHFFFAOYSA-N 0.000 description 3
- FKHLJDBUNQLFAC-UHFFFAOYSA-N CC.CN(C1=CC2=NC=CC=C2C=C1)C1=NC=CC=C1.C[Rn] Chemical compound CC.CN(C1=CC2=NC=CC=C2C=C1)C1=NC=CC=C1.C[Rn] FKHLJDBUNQLFAC-UHFFFAOYSA-N 0.000 description 3
- QLZQHHANRDSPFW-UHFFFAOYSA-N CC.CN(C1=CC=CC=C1)C1=CC2=CC=CC=C2N=C1.C[Rn] Chemical compound CC.CN(C1=CC=CC=C1)C1=CC2=CC=CC=C2N=C1.C[Rn] QLZQHHANRDSPFW-UHFFFAOYSA-N 0.000 description 3
- RJJXRGSJRWTQAF-UHFFFAOYSA-N CC.CN(C1=CC=CC=C1)C1=NC2=CC=CC=C2N=C1.C[Rn] Chemical compound CC.CN(C1=CC=CC=C1)C1=NC2=CC=CC=C2N=C1.C[Rn] RJJXRGSJRWTQAF-UHFFFAOYSA-N 0.000 description 3
- VJSQQGYNNPYXEP-JGQBTDMHSA-N CC.CN(C1=CC=CC=C1)C1=[Y]C2=[3H]C=[U][W]=C2C=C1.C[Rn].[V] Chemical compound CC.CN(C1=CC=CC=C1)C1=[Y]C2=[3H]C=[U][W]=C2C=C1.C[Rn].[V] VJSQQGYNNPYXEP-JGQBTDMHSA-N 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 3
- 229940097277 hygromycin b Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 210000005053 lamin Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108010075398 prelamin A Proteins 0.000 description 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 2
- ZGIKWINFUGEQEO-UHFFFAOYSA-N 3-bromoquinoline Chemical compound C1=CC=CC2=CC(Br)=CN=C21 ZGIKWINFUGEQEO-UHFFFAOYSA-N 0.000 description 2
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 2
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 2
- CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 2
- KDVBYUUGYXUXNL-UHFFFAOYSA-N 6-aminopyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C=N1 KDVBYUUGYXUXNL-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- WDLALBALDRYQNL-UHFFFAOYSA-N C1=CC=CC=C1.[V] Chemical compound C1=CC=CC=C1.[V] WDLALBALDRYQNL-UHFFFAOYSA-N 0.000 description 2
- TVNAXHWZULSFKV-UHFFFAOYSA-N CC.CN(C1=CC2=CC=CC=C2N=C1)C1=NC=CN=C1.C[Rn] Chemical compound CC.CN(C1=CC2=CC=CC=C2N=C1)C1=NC=CN=C1.C[Rn] TVNAXHWZULSFKV-UHFFFAOYSA-N 0.000 description 2
- MHLRTFYVSNDOEP-UHFFFAOYSA-N CC.CN(C1=CC2=CC=CN=C2C=C1)C1=NC=CN=C1.C[Rn] Chemical compound CC.CN(C1=CC2=CC=CN=C2C=C1)C1=NC=CN=C1.C[Rn] MHLRTFYVSNDOEP-UHFFFAOYSA-N 0.000 description 2
- YVQFZDIVIUAXFJ-UHFFFAOYSA-N CC.CN(C1=CC2=CC=NC=C2C=C1)C1=NC=CC=C1.C[Rn] Chemical compound CC.CN(C1=CC2=CC=NC=C2C=C1)C1=NC=CC=C1.C[Rn] YVQFZDIVIUAXFJ-UHFFFAOYSA-N 0.000 description 2
- WWEJCLYSMYEKSV-UHFFFAOYSA-N CC.CN(C1=CC=CC=C1)C1=CC2=NC=CC=C2C=C1.C[Rn] Chemical compound CC.CN(C1=CC=CC=C1)C1=CC2=NC=CC=C2C=C1.C[Rn] WWEJCLYSMYEKSV-UHFFFAOYSA-N 0.000 description 2
- JDQUVARNSNBBNO-UHFFFAOYSA-N CC.CN(C1=CC=CN=C1)C1=CC2=CC=CC=C2N=C1.C[Rn] Chemical compound CC.CN(C1=CC=CN=C1)C1=CC2=CC=CC=C2N=C1.C[Rn] JDQUVARNSNBBNO-UHFFFAOYSA-N 0.000 description 2
- BKWASDKNKIWEKT-UHFFFAOYSA-N CC.CN(C1=CC=NC=C1)C1=CC2=CC=CC=C2N=C1.C[Rn] Chemical compound CC.CN(C1=CC=NC=C1)C1=CC2=CC=CC=C2N=C1.C[Rn] BKWASDKNKIWEKT-UHFFFAOYSA-N 0.000 description 2
- DBHWVZGPPVOTEK-UHFFFAOYSA-N CC.CN(C1=CC=NC=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] Chemical compound CC.CN(C1=CC=NC=C1)C1=NC2=CC=CC=C2C=C1.C[Rn] DBHWVZGPPVOTEK-UHFFFAOYSA-N 0.000 description 2
- RGWYPZDDKQZIAE-UHFFFAOYSA-N CN(C1=NC=CC=C1)C1=NC2=C(Cl)C=CC=C2C=C1.C[Rn] Chemical compound CN(C1=NC=CC=C1)C1=NC2=C(Cl)C=CC=C2C=C1.C[Rn] RGWYPZDDKQZIAE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101150077556 LMNA gene Proteins 0.000 description 2
- 102000008201 Lamin Type A Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012152 bradford reagent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000030087 premature aging syndrome Diseases 0.000 description 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 2
- RJSRSRITMWVIQT-UHFFFAOYSA-N quinolin-6-amine Chemical compound N1=CC=CC2=CC(N)=CC=C21 RJSRSRITMWVIQT-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 208000034979 restrictive dermopathy Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LPDFGLZUUCLXGM-UHFFFAOYSA-N 2,6-dichloroquinoline Chemical compound N1=C(Cl)C=CC2=CC(Cl)=CC=C21 LPDFGLZUUCLXGM-UHFFFAOYSA-N 0.000 description 1
- PDOWLYNSFYZIQX-UHFFFAOYSA-N 2-bromo-3-methoxypyridine Chemical compound COC1=CC=CN=C1Br PDOWLYNSFYZIQX-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- IIDBMILLZRYZCH-UHFFFAOYSA-N 2-methyl-4-(trifluoromethoxy)aniline Chemical compound CC1=CC(OC(F)(F)F)=CC=C1N IIDBMILLZRYZCH-UHFFFAOYSA-N 0.000 description 1
- SVNCRRZKBNSMIV-UHFFFAOYSA-N 3-Aminoquinoline Chemical compound C1=CC=CC2=CC(N)=CN=C21 SVNCRRZKBNSMIV-UHFFFAOYSA-N 0.000 description 1
- PORGLLGXCAQORO-UHFFFAOYSA-N 3-bromo-2-methoxypyridine Chemical compound COC1=NC=CC=C1Br PORGLLGXCAQORO-UHFFFAOYSA-N 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- ALVVUWUQQNELGD-UHFFFAOYSA-N 4-pyridin-2-ylquinolin-2-amine Chemical compound C=12C=CC=CC2=NC(N)=CC=1C1=CC=CC=N1 ALVVUWUQQNELGD-UHFFFAOYSA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- JEEPKKVWXAIYFW-UHFFFAOYSA-N C.C1CCCCC1.[V] Chemical compound C.C1CCCCC1.[V] JEEPKKVWXAIYFW-UHFFFAOYSA-N 0.000 description 1
- NZCSMXWDUCLLKI-UHFFFAOYSA-N C.CC1=CC(NC2=CC=C(OC(F)(F)F)C=C2)=NC2=C1C=CC=C2.[Cl-] Chemical compound C.CC1=CC(NC2=CC=C(OC(F)(F)F)C=C2)=NC2=C1C=CC=C2.[Cl-] NZCSMXWDUCLLKI-UHFFFAOYSA-N 0.000 description 1
- MQQWPOSFYQGBNF-UHFFFAOYSA-N C.CC1=CC2=CC=CC=C2N=C1NC1=CC=C(OC(F)(F)F)C=C1.[Cl-] Chemical compound C.CC1=CC2=CC=CC=C2N=C1NC1=CC=C(OC(F)(F)F)C=C1.[Cl-] MQQWPOSFYQGBNF-UHFFFAOYSA-N 0.000 description 1
- RDVVVWFSMXCQHX-UHFFFAOYSA-N C.FC(F)(F)OC1=CC=C(NC2=NC3=CC=CC=C3C=C2)C=C1.[Cl-] Chemical compound C.FC(F)(F)OC1=CC=C(NC2=NC3=CC=CC=C3C=C2)C=C1.[Cl-] RDVVVWFSMXCQHX-UHFFFAOYSA-N 0.000 description 1
- ZKXWCAQATUHOEP-UHFFFAOYSA-N C.[C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C=C2)C=C1.[Cl-] Chemical compound C.[C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C=C2)C=C1.[Cl-] ZKXWCAQATUHOEP-UHFFFAOYSA-N 0.000 description 1
- NFAZIGWXHWXBDN-BJEBXASESA-N C1CCCCC1.CC.CC.CN(C)C1=[Y]C2=CC=C[W]=C2C=C1.[V] Chemical compound C1CCCCC1.CC.CC.CN(C)C1=[Y]C2=CC=C[W]=C2C=C1.[V] NFAZIGWXHWXBDN-BJEBXASESA-N 0.000 description 1
- KAUUMNUPULDVCV-UHFFFAOYSA-N CC.CC.CN(C1=CC2=CC=CC=C2N=C1)C1=NC=CC=C1 Chemical compound CC.CC.CN(C1=CC2=CC=CC=C2N=C1)C1=NC=CC=C1 KAUUMNUPULDVCV-UHFFFAOYSA-N 0.000 description 1
- XKFZZTRSLWUJDC-UHFFFAOYSA-N CC.CC.CN(C1=CC2=CC=CN=C2C=C1)C1=NC=CC=C1 Chemical compound CC.CC.CN(C1=CC2=CC=CN=C2C=C1)C1=NC=CC=C1 XKFZZTRSLWUJDC-UHFFFAOYSA-N 0.000 description 1
- PVHLKUJFZMLZFZ-UHFFFAOYSA-N CC.CC.CN(C1=CC=CC=C1)C1=NC2=CC=CC=C2C=C1 Chemical compound CC.CC.CN(C1=CC=CC=C1)C1=NC2=CC=CC=C2C=C1 PVHLKUJFZMLZFZ-UHFFFAOYSA-N 0.000 description 1
- UZTDYDZKOLPQOD-UHFFFAOYSA-N CC.CC.CN(C1=NC=CC=C1)C1=NC2=CC=CC=C2C=C1 Chemical compound CC.CC.CN(C1=NC=CC=C1)C1=NC2=CC=CC=C2C=C1 UZTDYDZKOLPQOD-UHFFFAOYSA-N 0.000 description 1
- GBGBPIZOYJCRCB-UHFFFAOYSA-N CC1=C2/C=N\C=C/C2=C(C)C(NC2=NC=C(C(F)(F)F)C=C2)=C1 Chemical compound CC1=C2/C=N\C=C/C2=C(C)C(NC2=NC=C(C(F)(F)F)C=C2)=C1 GBGBPIZOYJCRCB-UHFFFAOYSA-N 0.000 description 1
- FELITWFKOKSVOU-UHFFFAOYSA-O CC1=CC(NC2=NC3=C(Cl)C=CC=C3C=C2)=[NH+]C=C1.[Cl-] Chemical compound CC1=CC(NC2=NC3=C(Cl)C=CC=C3C=C2)=[NH+]C=C1.[Cl-] FELITWFKOKSVOU-UHFFFAOYSA-O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IBEDCVXKFQKPIF-UHFFFAOYSA-N FC1=CN=C(NC2=NC3=C(C=CC=C3F)C=C2)C=C1 Chemical compound FC1=CN=C(NC2=NC3=C(C=CC=C3F)C=C2)C=C1 IBEDCVXKFQKPIF-UHFFFAOYSA-N 0.000 description 1
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 description 1
- 101710125754 Farnesyl pyrophosphate synthase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000727979 Homo sapiens Remodeling and spacing factor 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027543 Micrognathia Diseases 0.000 description 1
- 208000002598 Micrognathism Diseases 0.000 description 1
- 101100012461 Mus musculus Zmpste24 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GKQWGUCKPKFKBV-UHFFFAOYSA-N NC1=CC=CN=C1NC1=CC2=CC=CC=C2N=C1 Chemical compound NC1=CC=CN=C1NC1=CC2=CC=CC=C2N=C1 GKQWGUCKPKFKBV-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 102100029771 Remodeling and spacing factor 1 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- XFDHDFQLUPUICW-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(NC2=CC=C3C=CC=C(Cl)C3=N2)N=C1C Chemical compound [C-]#[N+]C1=CC=C(NC2=CC=C3C=CC=C(Cl)C3=N2)N=C1C XFDHDFQLUPUICW-UHFFFAOYSA-N 0.000 description 1
- MWGOVWVAYRXQEL-UHFFFAOYSA-N [C-]#[N+]C1=CN=C(NC2=NC3=C(Cl)C=CC=C3C=C2)C=C1 Chemical compound [C-]#[N+]C1=CN=C(NC2=NC3=C(Cl)C=CC=C3C=C2)C=C1 MWGOVWVAYRXQEL-UHFFFAOYSA-N 0.000 description 1
- VRUOTLVQHCUBOO-UHFFFAOYSA-N [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C(C)=C2)C=C1 Chemical compound [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C(C)=C2)C=C1 VRUOTLVQHCUBOO-UHFFFAOYSA-N 0.000 description 1
- ZGNCSBVUTDNQCX-UHFFFAOYSA-N [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C=C2)C=C1 Chemical compound [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C=C2)C=C1 ZGNCSBVUTDNQCX-UHFFFAOYSA-N 0.000 description 1
- MXGNECYUZMPFNM-UHFFFAOYSA-N [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C=C2C)C=C1 Chemical compound [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3C=C2C)C=C1 MXGNECYUZMPFNM-UHFFFAOYSA-N 0.000 description 1
- PDYHMPZFCYYPER-UHFFFAOYSA-N [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3N=C2)C=C1 Chemical compound [C-]#[N+]C1=CN=C(NC2=NC3=CC=CC=C3N=C2)C=C1 PDYHMPZFCYYPER-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 108010054353 p21(ras) farnesyl-protein transferase Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108091005629 prenylated proteins Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 102220005011 rs58596362 Human genes 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention is generally dedicated to the use of compounds for the manufacture of compositions useful to treat diseases related to premature aging.
- the compounds and compositions containing them and compositions according to the invention may in particular be used to inhibit, prevent and/or treat Progeria.
- the present invention focuses on premature aging. Said premature aging may be encountered in patients suffering from various diseases and in particular from the Hutchinson-Gilford progeria syndrome (HGPS) and from the HIV infection.
- HGPS Hutchinson-Gilford progeria syndrome
- Hutchinson-Gilford progeria syndrome is a rare genetic disorder phenotypically characterized by many features of premature aging. It is clinically characterized by postnatal growth retardation, midface hypoplasia, micrognathia, premature atherosclerosis, absence of subcutaneous fat, alopecia and generalized osteodysplasia (Khalifa, 1989-Hutchinson-Gilford progeria syndrome: report of a Malawin family and evidence of autosomal recessive inheritance. Clin. Genet. 35, 125-132.).
- the appearance of patients is generally normal, but by 1 year of age patients show severe growth retardation, balding and sclerodermatous skin changes. They average about 1 m in height and usually weigh less than 15 kg even as teenagers. The age at death ranges from 7 to 28 years, with a median of 13.4 years. Over 80% of deaths are due to heart attacks or congestive heart failure.
- Premature aging syndrome has been observed in patients suffering from HIV infections.
- One mechanical pathway underlying said premature aging could be associated, as for the HGPS and as exposed beneath, with an aberrant splicing of the nuclear lamin A gene.
- protease inhibitors against HIV also block the transformation of prelamin A into lamin A as it turned out in HGPS.
- FTIs farnesyltransferase inhibitors
- Nicolas Levy's team has used a combination of a statin and an aminobisphosphonate to prevent the fixation of the fatty acid to the progerin, and thus reduce its toxicity (Varela et al., 2008—Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14, 767-772.).
- WO2006/081444 has been reported a method for reducing at least one cellular defect in a cell from a subject susceptible to a disease or condition characterized by farnesylation on an abnormally farnesylated form of a lamin, comprising administering to the cell a therapeutically effective dose of farnesylstransferase inhibitor.
- HMG-CoA hydroxymethylglutaryl-coenzyme A reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor, or one of their associated physiologically acceptable salts, in the preparation of a composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria, restrictive dermopathy or physiological aging.
- the present invention therefore relates to compounds of formula (I) as defined below for use as agents for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention moreover relates to a method of preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging, which comprises at least one step consisting in administering to a patient suffering there from an effective amount of a compound as defined in formula (I) below or one of its pharmaceutically acceptable salts.
- the present invention further relates to some particular derivatives as such, as defined below.
- the present invention also provides pharmaceutical compositions comprising at least one of said particular compounds.
- the present invention is based on a novel approach based on the inhibition of aberrant splicing leading to progerin production.
- the truncated Lamin A protein lacking the last 150 base pairs of exon 11 also called “progerin”, acting as a dominant negative mutant, is predicted to be responsible for the characteristic manifestations seen in HGPS patients.
- progerin acting as a dominant negative mutant
- therapeutic molecules that interfere with the usage of the cryptic splice site will prevent side effects associated with accumulation of progerin during physiological aging.
- the compounds according to the present invention prevent usage of the cryptic 5′ splice site in exon 11 of LMNA, allowing overcoming deleterious effect associated with progerin.
- a subject-matter of the present invention relates to a compound of formula (I)
- V means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridazine, a pyrimidine or a pyrazine group,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1, 2 or 3
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- Z is N or C
- Y is N or C
- W is N or C
- T N or C
- the present invention further relates to compounds of formula (I′)
- V means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridazine, a pyrimidine or a pyrazine group,
- R independently represents a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a —COOH group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxy group, a —COOH group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- Y is N or C
- W is N or C
- the present invention relates to a compound of formula (I′) as defined above, wherein Z is N, V is C, Y is C, X is N and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C and W is N, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention is directed to a compound of formula (I) wherein:
- Z is N or C
- Y is N or C
- X is N or C
- W is C
- n is equal to 1
- R is a hydrogen atom, a —COOH group, a (C 1 -C 3 )alkyl group or a (C 1 -C 3 )fluoroalkoxy group,
- the compound of formula (I) may be defined as a compound of formula (IIa) as follows:
- Z is N or C
- Y is N or C
- X is N or C
- the present invention extends to a compound of formula (IIa) as defined above for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention further relates to a compound of formula (IIb)
- Y is N or C
- X is N or C
- R 5 is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a (C 1 -C 3 )alkoxy group, a —NO 2 group and a (C 1 -C 3 )fluoroalkyl group, and
- R′ and R′′ are as defined above,
- the present invention further relates to a compound of formula (IIc)
- Y is N or C
- X is N or C
- R 5 is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a (C 1 -C 3 )alkoxy group, a —NO 2 group and a (C 1 -C 3 )fluoroalkyl group, and
- R′ and R′′ are as defined above,
- an additional subject-matter of the present invention is a compound of formula (Ia-1)
- R independently represent a hydrogen atom, a halogen atom, or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a —COOH group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group and a (C 1 -C 3 )alkoxy group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n 1 or 2, and advantageously 1, and
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxy group, a —COOH group and a —CN group,
- the present invention further relates to a compound of formula (Ia-1) as defined above, as such,
- R, R′′ and n are as defined above,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a —COOH group and a —CN group, and
- R and R′ are not simultaneously a hydrogen atom or a methyl group and R is not a bromine atom
- R 3 and R 4 are a hydrogen atom and the other is a hydrogen atom, a —COOH group or a (C 1 -C 3 )alkyl group, and
- R′′ is as defined above and is advantageously a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Ib-1)
- R independently represent a hydrogen atom, a halogen atom, or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a —COOH group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group, n is 1 or 2, and advantageously 1,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxy group, a —COOH group and a —CN group, and
- R′′ is as defined above and is advantageously a hydrogen atom
- the present invention further relates to a compound of formula (Ib-1) as defined above, as such
- R′ and R′′ are as defined above,
- n 1
- R is a (C 1 -C 3 )fluoroalkoxy group
- R 3 and R 4 is a hydrogen atom and the other is a (C 1 -C 3 )fluoroalkoxy group or a (C 1 -C 4 )alkoxy group,
- an additional subject-matter of the present invention is a compound of formula (Ic-1)
- R independently represent a hydrogen atom, a halogen atom, or a group chosen among a (C 1 -C 3 )alkyl group a —CN group, a —COOH group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group and a (C 1 -C 3 )alkoxy group,
- n 1 or 2, and advantageously 1,
- R′ is a hydrogen atom or a (C 1 -C 3 )alkyl group, and in particular is a hydrogen atom, and
- R′′ is as defined above and is advantageously a hydrogen atom
- the present invention further relates to a compound of formula (Ic-1) as defined above, as such
- R, R′ R′′ and n are as defined above, and
- R and R′ are not simultaneously a hydrogen atom
- R 3 and R 4 are a hydrogen atom and the other is a (C 1 -C 3 )alkyl group
- an additional subject-matter of the present invention is a compound of formula (Id-1):
- R independently represent a hydrogen atom, a halogen atom, or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a —COOH group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group and a —NO 2 group,
- n 1 or 2, and advantageously 1,
- R′ is a hydrogen atom or a (C 1 -C 3 )alkyl group, and in particular is a hydrogen atom, and
- R′′ is as defined above and is advantageously a hydrogen atom
- the compounds of formulae (I′), (IIa), (IIb), (IIc), (Ia-1), (Ib-1), (Ic-1) and (Id-1) can comprise one or more asymmetric carbon atoms. They can thus exist in the form of enantiomers or of diastereoisomers. These enantiomers, diastereoisomers and their mixtures, including the racemic mixtures, are encompassed within the scope of the present invention.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is C, U is C and W is N, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is N and is in para of Z, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is N and is in meta of Z and is in para of the bond linked to NR′′, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is N and is in meta of Z and is in para of the bond linked to NR′′, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in meta of Z and in ortho of the bond linked to NR′′, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is C, X is C, T is C, U is C and W is N, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in meta of Z and is in ortho of the bond linked to NR′′, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is C, X is C, T is N, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is N, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is C, U is N and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the compounds of the invention may exist in the form of free bases or of addition salts with pharmaceutically acceptable acids.
- Suitable physiologically acceptable acid addition salts of compounds of formula (I) include hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflate, mesylate, tosylate, formate, acetate and malate.
- the compounds of formula (I) and or salts thereof may form solvates (e.g. hydrates) and the invention includes all such solvates.
- the present invention relates to a compound of formula (I) as defined above for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging, wherein T is C, and Z, V, Y, X, U and W are as defined above.
- the present invention relates to a compound of formula (I) as defined above for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging, wherein W is C, and Z, V, Y, X, U and T are as defined above.
- the present invention relates to a compound of formula (I) as defined above for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging, wherein Z is N, V is C, U is C, T is C and W, Y and X are as defined above.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is C, U is C and W is N, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in para of Z, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is C, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is C, V is C, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in meta of Z and is in ortho of the bond linked to NR′′, Y is N, X is C, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is N and is in meta of Z and is in ortho of the bond linked to NR′′, Y is N, X is N, T is C, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention relates to a compound of formula (I) as defined above, wherein Z is N, V is C, Y is C, X is C, T is N, U is C and W is C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- an additional subject-matter of the present invention is a compound of formula (Ia)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NO 2 group, a (C 1 -C 3 )alkoxy group and a —NR 1 R 2 group,
- R 1 and R 2 are a hydrogen atom or a (C 1 -C 3 )alkyl group
- an additional subject-matter of the present invention is a compound of formula (Ib)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NR 1 R 2 group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a phenoxy group and a (C 1 -C 4 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is preferably 1 or 2
- n′ is as defined above and is preferably 1,
- R′ is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group and a (C 1 -C 4 )alkoxy group,
- an additional subject-matter of the present invention is a compound of formula (Ic)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkyl group, a —NR 1 R 2 group, a —COOR 1 group, a —NO 2 group and a (C 1 -C 3 )alkoxy group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- an additional subject-matter of the present invention is a compound of formula (Id)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkyl group and a (C 1 -C 3 )alkoxy group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Ie)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group and a (C 1 -C 3 )alkoxy group,
- an additional subject-matter of the present invention is a compound of formula (If)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Ig)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom or a halogen atom
- an additional subject-matter of the present invention is a compound of formula (Ih)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (II)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkoxy group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Ij)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkyl group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Ik)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 )alkyl group
- an additional subject-matter of the present invention is a compound of formula (Il)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Im)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Io)
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 )fluoroalkyl group
- an additional subject-matter of the present invention is a compound of formula (Ip)
- R represents a hydrogen atom
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom
- an additional subject-matter of the present invention is a compound of formula (Iq)
- R independently represent a hydrogen atom, a (C 1 -C 3 )alkoxy group or a (C 1 -C 3 )fluoroalkoxy group
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom or a group chosen among a —NR 1 R 2 group, a N-methylpiperazinyl group, a (C 1 -C 3 )alkoxy group and a morpholino group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- an additional subject-matter of the present invention is a compound of formula (Ir)
- R independently represent a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 1,
- R′ is a hydrogen atom or a group chosen among a —NR 1 R 2 group, a morpholino group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- an additional subject-matter of the present invention is a compound of formula (Iee)
- R independently represent a hydrogen atom, a (C 1 -C 3 )alkyl group or a (C 1 -C 3 )fluoroalkyl group,
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above and is advantageously 2,
- R′ is a hydrogen atom or a (C 1 -C 3 )alkyl group
- the present invention further relates to a compound chosen among compounds of formulae (Ia), (Ib), (Ic), (Id), (Ie), (Ii), (Ij), (Ik), (Io), (Ip), (Ir) and their pharmaceutically acceptable salts for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the present invention particularly focuses on a compound of formula (Ia)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 is a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 1,
- n′ is as defined above and more preferably is 1,
- R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 )alkyl group
- the present invention more preferably focuses on compounds of formula (Ia′),
- R independently represent a hydrogen atom, a —COOR 1 group or a (C 1 -C 3 ) alkyl group,
- R 1 is as defined above,
- R′′ is a hydrogen atom
- n 1 or 2
- the present invention particularly focuses on a compound of formula (Ib)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkoxy group and a phenoxy group,
- R 1 is a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 1,
- n′ is as defined above
- R′ is a hydrogen atom
- the present invention particularly focuses on a compound of formula (Ic)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NO 2 group and a (C 1 -C 3 )alkoxy group,
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 1,
- n′ is as defined above
- R′ is a hydrogen atom
- the present invention particularly focuses on a compound of formula (Ie)
- R represents a hydrogen atom
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 1,
- n′ is as defined above
- R′ is a hydrogen atom or a halogen atom
- the present invention particularly focuses on a compound of formula (II)
- R independently represent a hydrogen atom or a (C 1 -C 3 )alkoxy group
- R′′ is as defined above and is advantageously a hydrogen atom
- n is as defined above and is advantageously 1,
- n′ is as defined above
- R′ is a hydrogen atom
- the present invention particularly focuses on a compound of formula (Ij)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkyl group,
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 2,
- n′ is as defined above
- R′ is a hydrogen atom
- the present invention particularly focuses on a compound of formula (Ik)
- R represents a hydrogen atom
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 1,
- n′ is as defined above
- R′ is a hydrogen atom
- the present invention particularly focuses on a compound of formula (Io)
- R independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group and a —CN group,
- R′′ is as defined above and more preferably is a hydrogen atom
- n is as defined above and more preferably is 1,
- n′ is as defined above
- R′ is a hydrogen atom
- the present invention relates to a compound of formula (Ib), (Ie) or (Ij) as defined above or one of its pharmaceutically acceptable salts, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- the compound for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging is chosen from:
- the present invention therefore extends to compounds (2), (3), (4), (5), (7), (8), (9), (10), (13), (15), (16), (17), (18), (25), (26), (28), (31), (32), (33), (34), (35), (36), (38), (39), (41), (42), (45), (59), (61), (82), (83), (86), (102), (105), (106), (107), (108), (109), (113), (120), (123), (125), (128), (135), (136), (137), (138), (142), (145), (146) and (147) or one of its pharmaceutically acceptable salts for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- Some of said preceding compounds are new and form part of the present invention: (2), (5), (7), (8), (10), (13), (15), (16), (18), (25), (26), (28), (31), (32), (33), (34), (35), (36), (38), (39), (41), (42), (59), (61), (82), (83), (86), (102), (105), (106), (107), (108), (109), (113), (125), (128), (135), (136), (137), (138), (142), (145), (146) and (147) or one of its pharmaceutically acceptable salts such as hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflate, mesylate, tosylate, formate, acetate and malate.
- pharmaceutically acceptable salts such as hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflat
- the compounds of formulae (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) and (Iee) can comprise one or more asymmetric carbon atoms. They can thus exist in the form of enantiomers or of diastereoisomers. These enantiomers, diastereoisomers and their mixtures, including the racemic mixtures, are encompassed within the scope of the present invention.
- the present invention encompasses compounds of formula (Ig)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
- n 1 or 2
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- the present invention encompasses compounds of formula (If)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C3)alkoxy group,
- n 1 or 2
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- the present invention encompasses compounds of formula (Ih)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
- n 1 or 2
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- the present invention encompasses compounds of formula (II)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
- n 1 or 2
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- the present invention encompasses compounds of formula (Im)
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, and a (C 1 -C 3 )alkoxy group,
- n 1 or 2
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- the present invention encompasses compounds of formula (Ia), as such,
- R′′ and n are as defined in formula (Ia),
- n′ 1,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a —NO 2 group, a (C 1 -C 3 )fluoroalkoxy group and a (C 1 -C 3 )alkoxy group,
- R′ is a hydrogen atom or a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —COOR 1 group, and a —CN group,
- R 1 is a hydrogen atom or a (C 1 -C 3 )alkyl group:
- R is not a methyl group in ortho or para position with respect to Z, Z being N,
- R′ is a hydrogen atom, R is not a bromine atom or a chlorine atom,
- R when R is a hydrogen atom, R′ is not a methyl or ethyl group, a —COOH group, a COOC 2 H 5 group or a bromine atom, said bromine atom being in ortho position of the bond linked to NR′′,
- R independently represent a hydrogen atom, a —NO 2 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )alkoxy group, a —CN group, a (C 1 -C 3 ) alkyl group, a —COOR 1 group or a halogen atom,
- R′′ is as defined in formula (Ia),
- R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 ) alkyl group
- n 1 or 2
- R is not a methyl group in ortho or para position with respect to Z, Z being N,
- R is not a bromine atom or a chlorine atom when R′ is a hydrogen atom
- the present invention more preferably focuses on compounds of formula (Ia′), as such,
- R independently represent a hydrogen atom, a —COOR 1 group, a (C 1 -C 3 ) alkyl group, —NO 2 group, a (C 1 -C 3 )fluoroalkyl group, a —CN group, a halogen atom or a hydroxyl group,
- R′′ is as defined in formula (Ia),
- the present invention encompasses compounds of formula (Ib), as such,
- R′ and R′′ are as defined in formula (Ib),
- n 1
- R is a hydrogen atom or a (C 1 -C 3 )fluoroalkoxy group
- the present invention encompasses compounds of formula (Ic), as such,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )fluoroalkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1 or 2, and advantageously 1,
- n′ 1 or 2
- R′′ is as defined in formula (Ic),
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R and R′ are not simultaneously a hydrogen atom
- R is not a bromine atom when R′ is a hydrogen atom
- R is a hydrogen atom, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )alkoxy group, a —NO 2 group or a —COOR 1 group,
- n, R′′, n′ and R 1 are as defined in formula (Ic),
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group, and is preferably a hydrogen atom,
- the present invention encompasses compounds of formula (Id), as such,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group and a —NR 1 R 2 group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1 or 2, and advantageously 1,
- n′ 1 or 2
- R′′ is as defined in formula (I) and is advantageously a hydrogen atom
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R′ when R′ is a hydrogen atom, R is different from a —NO 2 group, a —NH 2 group or a —COOH group,
- R is a hydrogen atom, a (C 1 -C 3 )alkyl group, a (C 1 -C 3 )alkoxy group or a (C 1 -C 3 )fluoro alkyl group,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group, and advantageously a hydrogen atom,
- R′′ is as defined in formula (I) and is advantageously a hydrogen atom
- n 1 or 2, and advantageously 1,
- n′ 1 or 2
- the present invention encompasses compounds of formula (Ie)
- R, R′, R′′ n and n′ are as defined in formula (I),
- R′ is not a bromine atom
- the present invention encompasses compounds of formula (II′), as such,
- R 3 is a (C 1 -C 3 )fluoroalkyl group or a (C 1 -C 3 )alkyl group,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and is advantageously a hydrogen atom
- n′ is as defined above and is advantageously 1,
- R 3 is not a methyl group or a trifluoromethyl group
- the present invention encompasses compounds of formula (Ij′), as such,
- R 4 is a (C 1 -C 3 )fluoroalkyl group or a (C 1 -C 3 )alkyl group,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and is advantageously a hydrogen atom
- n′ is as defined above and is advantageously 1,
- R 4 is not a methyl group
- the present invention encompasses compounds of formula (Ij′′), as such,
- R 4 is a (C 1 -C 3 )fluoroalkyl group or a (C 1 -C 3 )alkyl group,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and is advantageously a hydrogen atom
- n′ is as defined above and is advantageously 1,
- the present invention encompasses compounds of formula (Ij′′′), as such,
- R 4 is a (C 1 -C 3 )fluoroalkyl group or a (C 1 -C 3 )alkyl group,
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′′ is as defined above and is advantageously a hydrogen atom
- n′ is as defined above and is advantageously 1,
- R 4 is not an ethyl group or a methyl group
- R 4 is not a methyl group
- the present invention encompasses compounds of formula (Ik) as such,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1 or 2, and is advantageously 1,
- n′ 1 or 2
- R′′ is as defined in formula (Ik)
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R is a hydrogen atom
- R′′ is as defined in formula (Ik),
- R′ is a hydrogen atom, a halogen atom or a (C 1 -C 3 ) alkyl group
- n 1 or 2, and is advantageously 1,
- n′ 1 or 2
- the present invention encompasses compounds of formula (Io), as such,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1, 2 or 3
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R is a hydrogen atom and n′ is 1, R′ is not a hydroxyl group
- R is a hydrogen atom, a (C 1 -C 3 )alkyl group or a —CN group,
- n 1, 2 or 3
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group, and preferably is a hydrogen atom or a (C 1 -C 3 )alkyl group,
- R 1 is as defined in formula (Io),
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- the present invention encompasses compounds of formula (Ip), as such,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1 or 2, and advantageously 1,
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R and R′ are not simultaneously a hydrogen atom
- the present invention encompasses compounds of formula (Ir), as such,
- R independently represent a hydrogen atom, a halogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group and a (C 1 -C 3 )alkoxy group,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- n 1 or 2, and advantageously 1,
- n′ 1 or 2
- R′ is a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 3 )alkoxy group and a —CN group,
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- R is a hydrogen atom or a (C 1 -C 3 )alkyl group
- R′ is a (C 1 -C 3 )alkoxy group or a —NR 1 R 2 group
- R′′ is a hydrogen atom or a (C 1 -C 4 )alkyl group
- n and n′ are 1,
- R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group
- compounds (1), (2), (5)-(8), (10)-(16), (18), (21)-(44), (46)-(75), (77)-(84), (86)-(119), (121), (124)-(130), (132), (135)-(141), (143)-(147), (149)-(168) and their pharmaceutically acceptable salts are of particular interest.
- the present invention therefore extends to compounds (1), (2), (5)-(8), (10)-(16), (18), (21)-(44), (46)-(75), (77)-(84), (86)-(119), (121), (124)-(130), (132), (135)-(141), (143)-(147), (149)-(168) and their pharmaceutically acceptable salts, as such.
- compounds (1), (2), (5)-(7), (10)-(16), (18), (21)-(44), (46)-(74), (105)-(108), (124)-(130), (135)-(141), (145)-(147), (150)-(154), (159), (160)-(165), (168) and their pharmaceutically acceptable salts are of particular interest.
- the present invention therefore extends more preferably to compounds (1), (2), (5)-(7), (10)-(16), (18), (21)-(44), (46)-(74), (105)-(108), (124)-(130), (135)-(141), (145)-(147), (150)-(154), (159), (160)-(165), (168) and their pharmaceutically acceptable salts, such as hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflate, mesylate, tosylate, formate, acetate and malate.
- pharmaceutically acceptable salts such as hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflate, mesylate, tosylate, formate, acetate and malate.
- the present invention extends to compounds (2), (5), (7), (10), (13), (15), (16), (18), (25), (26), (28), (31)-(36), (38), (39), (41), (42), (59), (61), (105)-(108), (125), (128), (135)-(138), (145)-(147) and their pharmaceutically acceptable salts, such as hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflate, mesylate, tosylate, formate, acetate and malate.
- pharmaceutically acceptable salts such as hydrochloride, hydrobromide, tartrate, fumarate, citrate, trifluoroacetate, ascorbate, triflate, mesylate, tosylate, formate, acetate and malate.
- the new compounds of the present invention i.e. compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (Ik), (Ii′), (Ij′), (Ij′′), (Ij′′′), (Io), (Ip) and (Ir) and the specific compounds as listed above, are not only useful as agent for inhibiting, preventing or treating premature aging but can also be used as agent for inhibiting, preventing or treating AIDS or cancer, and more particularly colorectal cancer, pancreatic cancer, lung cancer including non-small cell lung cancer, breast cancer, bladder cancer, gall bladder cancer, liver cancer, thyroid cancer, melanoma, uterine/cervical cancer, oesophageal cancer, kidney cancer, ovarian cancer, prostate cancer, head and neck cancer and stomach cancer, etc.
- the compounds of the present invention can be prepared by conventional methods of organic synthesis practiced by those skilled in the art.
- the general reaction sequences outlined below represent a general method useful for preparing the compounds of the present invention and are not meant to be limiting in scope or utility.
- the synthesis is based on a coupling reaction alternatively starting from a halogeno-bicycle of formula (III), wherein X, Y, W, T, U, n′, R′ and R′′ are as defined above and X′ is a chlorine atom or a bromine atom or from a chloro-monocycle of formula (V), wherein Z, V, n and R are as defined above and X′ is a chlorine atom or a bromine atom.
- a halogeno-bicycle of formula (III) wherein X, Y, W, T, U, n′, R′ and R′′ are as defined above and X′ is a chlorine atom or a bromine atom or from a chloro-monocycle of formula (V), wherein Z, V, n and R are as defined above and X′ is a chlorine atom or a bromine atom.
- the compound of formula (III) is placed in a protic solvent such as tert-butanol.
- the compound of formula (IV) is then added in a molar ratio ranging from 1 to 1.5 with respect to the compound of formula (III) in presence of an inorganic base, such as Cs 2 CO 3 or K 2 CO 3 in a molar ratio ranging from 1 and 2, in the presence of a diphosphine, such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) or X-Phos (2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) in an amount ranging from 2 mol % to 10 mol % relative to the total amount of compound of formula (III), and in the presence of a catalyst, such as Pd(OAc) 2 or Pd 2 dba 3 in an amount ranging from 2 mol % to 10
- the reaction mixture can then be heated at a temperature ranging from 80 to 120° C., for example at 90° C. and stirred for a time ranging form 15 to 25 hours, for example during 20 hours under inert gas and for example argon.
- the reaction mixture can be concentrated under reduced pressure.
- the compound of formula (V) is placed in a protic solvent such as tert-butanol.
- the compound of formula (VI) is then added in a molar ratio ranging from 1 to 1.5 with respect to the compound of formula (V) in presence of an inorganic base, such as Cs 2 CO 3 or K 2 CO 3 in a molar ratio ranging from 1 to 2, in the presence of a diphosphine, such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) or X-Phos (2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) in an amount ranging from 2 mol % to 10 mol % relative to the total amount of compound of formula (V), and in the presence of a catalyst, such as Pd(OAc) 2 or Pd 2 dba 3 in an amount ranging from 2 mol % to 10
- the reaction mixture can then be heated at a temperature ranging from 80 to 120° C., for example at 90° C. and stirred for a time ranging form 15 to 25 hours, for example during 20 hours under inert gas and for example argon.
- the reaction mixture can be concentrated under reduced pressure.
- the compound of formula (V) is placed in a protic solvent such as tert-butanol.
- the compound of formula (VI) is then added in a 1.1 molar ratio with respect to the compound of formula (V) in presence of Cs 2 CO 3 in a 2.8 molar ratio, in the presence of Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) in a 2 mol % amount relative to the total amount of compound of formula (V), and in the presence of a Pd(OAc) 2 , in a 2 mol % amount relative to the total amount of compound of formula (V).
- Xantphos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
- reaction mixture is then heated at 90° C., and stirred during 20 hours, under argon.
- the reaction mixture is concentrated under reduced pressure and the resulting residue is diluted with ethyl acetate.
- the organic phase is then washed twice with water, dried on magnesium sulphate, filtered and concentrated under reduced pressure.
- the residue could then be purified by column chromatography on silica gel to yield pure compound (13), (108), (16), (123), (38).
- the compounds of the invention have been the subject of pharmacological tests which have demonstrated their relevance as active substances in therapy and in particular for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.
- mutant and wild type constructs FIG. 1A , for schematic representation
- TOPO-TA cloning vector in which is inserted a minigene containing 142 nts of ⁇ -Globin first exon, 130 nts ⁇ -Globin first intron, 270 nts LMNA exon 11 either wild type or mutant, 322 nts intron 11 and 46 nts exon 12.
- the luciferase assay is an extremely sensitive and rapid assay. Linear results are seen over at least eight orders of magnitude of enzyme concentration. Moreover, the luciferase assay is well suited for high-throughput applications.
- MTS Mid-throughput screening
- Plasmids constructs Plasmids constructs. LMNA sequences (1278 bp of exon 11, intron 11 and 46 bp of exon 11) were PCR-amplified from either control or patient's cells genomic DNA with specific primer PCR fragments were purified with Concert Rapid PCR purification system (Invitrogen) and subcloned at the BamHI and EcoRI restriction sites of the pSp ⁇ m3S1 plasmid containing the ⁇ Globin cassette (Labourier et al., 1999—Recognition of exonic splicing enhancer sequences by the Drosophila splicing repressor RSF1. Nucleic Acids Res.
- LMNAlucWT Fyrefly luciferase cDNA
- LNAlucMut usage of the cryptic splice site of mutated exon 11
- HeLa cells transfections with splicing reporter constructs were performed with lipofectAMINE 2000 reagent (Invitrogen) according to the manufacturer's instructions. Twenty four hours after transfection, total RNA was purified with RNA-PLUSTM (Quantum Bioprobe). First strand cDNA was synthesized from 2 ⁇ g of RNA with the Amersham-Pharmacia First strand cDNA synthesis kit. For PCR analyses, 1/15 of the reaction was amplified with Taq polymerase (Invitrogen). The cycle number was kept to a minimum to maintain linearity. PCR products were separated on a 1.5% agarose gel containing ethidium bromide and visualized under UV light.
- a stable 293 cell line containing a single copy of LMNAlucMut minigene was obtained using the Flp-In system from (Invitrogen) according to manufacture procedure. Several clones were obtained and only one clone was used to screen the whole chemical library (293FLP LMNA LUC cells #8).
- HeLa cells nuclear extracts were prepared according to (Dignam et al., 1983—Eukaryotic gene transcription with purified components. Methods Enzymol. 101, 582-598). Pre-mRNA were synthesized by in vitro transcription in the presence of 20 units of T7 RNA polymerase,
- D-MEM Dulbecco's Modified Eagle Medium (1 ⁇ )+GlutaMAX, liquid (invitrogen 31966-021)
- D-PBS Dulbecco's Phosphate Buffered Saline (1 ⁇ ), liquid (invitrogen 14190-169)
- FCS Foetal calf serum
- V-shape In a 96 Well Plate sterile, V-shape one put 0.5 ⁇ l of drug compounds at 50 mM and then add 49.5 ⁇ l of 10% DMSO.
- Cell concentration is brought at 105 cells per ml with DMEM+Hygromycin B to have 104 cells per 100 ⁇ l.
- the compounds according to the present invention demonstrate an increase of luciferase activity ranging between 3 and 7 fold compared to control untreated MutLMNA-luc cell line.
- said compounds may be useful to inhibit, prevent and/or treat diseases with premature aging and that are likely related to an aberrant splicing of the nuclear lamin A gene.
- said disease may include Hutchinson Guilford Progeria Syndrome (HGPS), progeria, premature aging associated with HIV infection, muscular dystrophy, Charcot-Marie-Tooth disorder, Werner syndrome, but also atherosclerosis, insulin resistant type II diabetes, cataracts, osteoporosis and aging of the skin such as restrictive dermopathy.
- HGPS Hutchinson Guilford Progeria Syndrome
- an effective amount of a said compound may be administered to a patient suffering from premature aging and in particular from progeria, and from the previous cited diseases.
- the present invention is also related to the use of at least a compound chosen among a compound of anyone of formula (I), (I′), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) or (Iee) as defined above, and compounds (1) to (168) as defined above, or one of its pharmaceutically acceptable salts according to the present invention for the manufacture of a pharmaceutical composition intended for the treatment of pathological or nonpathological conditions linked with premature aging and in particular progeria.
- the present invention also encompasses pharmaceutical compositions comprising at least a compound chosen among new compounds of formula (Ia), (Ia′), (Ic), (Id), (Ii′), (Ij′), (Ij′′), (Ij′′′), (Ik), (Io), (Ip) and (Ir) as defined above and compounds (1), (2), (5)-(7), (10)-(16), (18), (21)-(44), (46)-(74), (105)-(108), (124)-(130), (135)-(141), (145)-(147), (150)-(154), (159), (160)-(165), (168), as defined above or any pharmaceutically acceptable salt thereof.
- compositions contain an effective amount of said compound, and one or more pharmaceutical excipients.
- excipients are selected according to the dosage form and the desired mode of administration.
- any pharmaceutical form which is suitable for enteral or parenteral administration, in association with appropriate excipients, for example in the form of plain or coated tablets, hard gelatine, soft shell capsules and other capsules, suppositories, or drinkable, such as suspensions, syrups, or injectable solutions or suspensions, in doses which enable the daily administration of from 0.1 to 1000 mg of active substance.
- the present invention is also related to the use of at least a compound chosen among a compound of anyone of formula (I), (I′), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir) or (Iee) as defined above, and compounds (1) to (168) as defined above, or one of its pharmaceutically acceptable salts according to the present invention for the manufacture of a pharmaceutical composition intended for inhibiting, preventing and/or treating pathological or nonpathological conditions linked with premature aging and in particular progeria but also all the previous listed diseases.
- the present invention further relates to a method of treatment of patients suffering form premature aging or anyone of the previous listed disease, which comprises at least a step of administration to a patient suffering thereof of an effective amount of a compound of anyone of formula (I), (I′), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (Io), (Ip), (Iq), (Ir), (Iee) and (1) to (168) or one of its pharmaceutically acceptable salts.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/377,753 US20120329796A1 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18655209P | 2009-06-12 | 2009-06-12 | |
US18654409P | 2009-06-12 | 2009-06-12 | |
EP09162630A EP2261214A1 (en) | 2009-06-12 | 2009-06-12 | Compounds useful to treat premature aging and in particular progeria |
EP20090305540 EP2266972A1 (en) | 2009-06-12 | 2009-06-12 | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
EP09162630.9 | 2009-06-12 | ||
EP09305540.8 | 2009-06-12 | ||
US13/377,753 US20120329796A1 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
PCT/IB2010/052652 WO2010143170A2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/052652 A-371-Of-International WO2010143170A2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/377,760 Continuation-In-Part US9145367B2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating AIDS |
PCT/IB2010/052651 Continuation-In-Part WO2010143169A2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating aids |
US14/256,334 Continuation-In-Part US9908869B2 (en) | 2009-06-12 | 2014-04-18 | Compounds useful for treating aids |
US15/486,836 Continuation-In-Part US10253020B2 (en) | 2009-06-12 | 2017-04-13 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120329796A1 true US20120329796A1 (en) | 2012-12-27 |
Family
ID=43309298
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/377,760 Active 2030-07-24 US9145367B2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating AIDS |
US13/377,745 Abandoned US20120277230A1 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating cancer |
US13/377,753 Abandoned US20120329796A1 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating premature aging and in particular progeria |
US14/087,762 Active US9108919B2 (en) | 2009-06-12 | 2013-11-22 | Compounds useful for treating cancer |
US14/256,334 Active US9908869B2 (en) | 2009-06-12 | 2014-04-18 | Compounds useful for treating aids |
US14/789,149 Active US9637475B2 (en) | 2009-06-12 | 2015-07-01 | Compounds for treating cancer |
US14/789,250 Active US10017498B2 (en) | 2009-06-12 | 2015-07-01 | Compounds useful for treating AIDS |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/377,760 Active 2030-07-24 US9145367B2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating AIDS |
US13/377,745 Abandoned US20120277230A1 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating cancer |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/087,762 Active US9108919B2 (en) | 2009-06-12 | 2013-11-22 | Compounds useful for treating cancer |
US14/256,334 Active US9908869B2 (en) | 2009-06-12 | 2014-04-18 | Compounds useful for treating aids |
US14/789,149 Active US9637475B2 (en) | 2009-06-12 | 2015-07-01 | Compounds for treating cancer |
US14/789,250 Active US10017498B2 (en) | 2009-06-12 | 2015-07-01 | Compounds useful for treating AIDS |
Country Status (24)
Country | Link |
---|---|
US (7) | US9145367B2 (lt) |
EP (6) | EP3521283B1 (lt) |
JP (8) | JP5826745B2 (lt) |
KR (14) | KR101973348B1 (lt) |
CN (13) | CN106928205B (lt) |
AU (3) | AU2010258295B2 (lt) |
BR (5) | BR122019013686B1 (lt) |
CA (5) | CA2764027C (lt) |
CU (4) | CU24124B1 (lt) |
DK (4) | DK3517534T3 (lt) |
ES (3) | ES2938532T3 (lt) |
FI (3) | FI2440546T3 (lt) |
HK (8) | HK1173153A1 (lt) |
HR (2) | HRP20230143T1 (lt) |
HU (2) | HUE061262T2 (lt) |
LT (1) | LT2440547T (lt) |
MX (9) | MX364279B (lt) |
PL (3) | PL2440546T3 (lt) |
PT (4) | PT2440545T (lt) |
RU (1) | RU2567752C2 (lt) |
SI (1) | SI2440547T1 (lt) |
TR (1) | TR201910781T4 (lt) |
WO (3) | WO2010143170A2 (lt) |
ZA (2) | ZA201109032B (lt) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11441181B2 (en) | 2013-01-17 | 2022-09-13 | Abivax | miRNA-124 as a biomarker |
US11649211B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
US11992499B2 (en) | 2018-12-20 | 2024-05-28 | Abivax | Quinoline derivatives for use in the treatment of inflammation diseases |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019008390A (es) * | 2009-06-12 | 2019-09-09 | Abivax | Compuestos utiles para tratar cancer. |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
KR101973348B1 (ko) | 2009-06-12 | 2019-04-26 | 아비박스 | 조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물 |
JP5696856B2 (ja) | 2009-09-03 | 2015-04-08 | バイオエナジェニックス | Paskの阻害用複素環式化合物 |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
AU2012204353B2 (en) | 2011-01-05 | 2016-12-08 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
AU2012223232B2 (en) | 2011-03-02 | 2017-05-25 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
FR2987627B1 (fr) | 2012-03-05 | 2016-03-18 | Splicos | Utilisation de rbm39 comme biomarqueur |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
US20150150869A1 (en) * | 2012-06-20 | 2015-06-04 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
US9487526B2 (en) | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
JP2014237624A (ja) * | 2012-10-23 | 2014-12-18 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
GB201301571D0 (en) * | 2012-11-27 | 2013-03-13 | Fundanci N Pedro Barri De La Maza | Product and use |
US20140194465A1 (en) * | 2013-01-04 | 2014-07-10 | Novarx Corporation | Compositions for treatment of cancer |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
HRP20211839T1 (hr) * | 2013-07-05 | 2022-03-04 | Abivax | Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima |
WO2015005491A1 (ja) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
JP6526034B2 (ja) | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Gpr6のピリドピラジンモジュレーター |
DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
LT3122358T (lt) | 2014-03-26 | 2021-04-12 | Astex Therapeutics Ltd. | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui |
EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
CA2973942C (en) | 2015-01-30 | 2023-07-11 | Centre National De La Recherche Scientifique (Cnrs) | Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
EP3390364B1 (en) | 2015-12-17 | 2020-07-15 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity and/or cancer cells growth |
WO2017134098A1 (en) * | 2016-02-03 | 2017-08-10 | Janssen Pharmaceutica Nv | Tau pet imaging ligands |
WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
EP3484528B1 (en) | 2016-07-18 | 2020-11-25 | Janssen Pharmaceutica NV | Tau pet imaging ligands |
CN106496061B (zh) * | 2016-10-20 | 2018-06-05 | 湘潭大学 | 一种萃取分离酰化反应液中乙酰精胺的方法 |
AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
WO2019045655A1 (en) | 2017-08-29 | 2019-03-07 | Chulabhorn Foundation | DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE |
US20200039989A1 (en) * | 2018-03-01 | 2020-02-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk/clk and uses thereof |
WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
KR20220009442A (ko) | 2019-05-15 | 2022-01-24 | 아론바이오 리미티드 | 암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자 |
EP3858336A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
EP3858815A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
US20230218605A1 (en) * | 2020-01-31 | 2023-07-13 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
CA3172179A1 (en) | 2020-03-20 | 2021-09-23 | Jamal Tazi | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
EP4063351A1 (en) | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
WO2022247920A1 (zh) | 2021-05-27 | 2022-12-01 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
KR20230072900A (ko) | 2021-11-18 | 2023-05-25 | 동우 화인켐 주식회사 | 마이크로 led 구조체 및 이의 제조방법 |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
WO2023138657A1 (zh) * | 2022-01-24 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030207886A1 (en) * | 2000-03-17 | 2003-11-06 | Pluecker Frank | Preparation containing quinoxaline derivatives |
US20060089380A1 (en) * | 2002-07-16 | 2006-04-27 | Prana Biotechnology Ltd. | 8-Hydroxy quinoline derivatives |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR400973A (fr) | 1909-03-19 | 1909-08-13 | Jean Victor Massillon | Nouveau sertisseur à main pour la fabrication des cartouches |
GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
BE486034A (lt) | 1947-11-28 | |||
DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
FR2645861A1 (fr) * | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
CA2368688C (en) * | 1999-04-05 | 2009-08-11 | City Of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
PL373301A1 (en) | 2001-01-22 | 2005-08-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
ES2355472T3 (es) | 2002-05-22 | 2011-03-28 | Amgen Inc. | Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor. |
WO2004009552A1 (en) * | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
WO2006081444A2 (en) | 2005-01-28 | 2006-08-03 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
WO2004078731A1 (fr) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
EP1601357A4 (en) | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
CN1882345A (zh) * | 2003-10-16 | 2006-12-20 | 希龙公司 | 作为raf激酶抑制剂以治疗癌症的2,6-二取代的喹唑啉、喹喔啉、喹啉和异喹啉 |
MXPA06005657A (es) * | 2003-11-19 | 2006-08-23 | Array Biopharma Inc | Inhibidores heterociclicos de mek y metodos para usarlos. |
CA2585490A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
CN101213260A (zh) | 2005-06-29 | 2008-07-02 | 株式会社Adeka | 树脂添加剂组合物和其树脂组合物 |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
US8030487B2 (en) * | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
CN101663279A (zh) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
FR2912745A1 (fr) * | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
CA2681481A1 (en) * | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
TWI371445B (en) | 2007-05-17 | 2012-09-01 | Lg Chemical Ltd | New anthracene derivatives and organic electronic device using the same |
UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
AU2008286760A1 (en) | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-HT6 receptor affinity |
WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
KR100974562B1 (ko) * | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
CA2747790A1 (en) * | 2009-01-05 | 2010-07-08 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
US20110275791A1 (en) * | 2009-01-06 | 2011-11-10 | Ziad Mallat | A B Cell Depleting Agent for the Treatment of Atherosclerosis |
WO2010079123A2 (en) * | 2009-01-06 | 2010-07-15 | Dsm Ip Assets B.V. | Process for resveratrol intermediate |
MX2019008390A (es) | 2009-06-12 | 2019-09-09 | Abivax | Compuestos utiles para tratar cancer. |
EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
KR101973348B1 (ko) | 2009-06-12 | 2019-04-26 | 아비박스 | 조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물 |
US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
US20150272959A1 (en) | 2012-10-04 | 2015-10-01 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
JP2015120566A (ja) * | 2013-12-20 | 2015-07-02 | ニチユ三菱フォークリフト株式会社 | 荷役車両 |
-
2010
- 2010-06-14 KR KR1020187025624A patent/KR101973348B1/ko active IP Right Grant
- 2010-06-14 AU AU2010258295A patent/AU2010258295B2/en active Active
- 2010-06-14 BR BR122019013686-6A patent/BR122019013686B1/pt active IP Right Grant
- 2010-06-14 ES ES10757474T patent/ES2938532T3/es active Active
- 2010-06-14 CN CN201710158473.8A patent/CN106928205B/zh active Active
- 2010-06-14 CA CA2764027A patent/CA2764027C/en active Active
- 2010-06-14 KR KR1020187025623A patent/KR101982461B1/ko active IP Right Grant
- 2010-06-14 CN CN201510023124.6A patent/CN104844570B/zh active Active
- 2010-06-14 SI SI201032127T patent/SI2440547T1/sl unknown
- 2010-06-14 HR HRP20230143TT patent/HRP20230143T1/hr unknown
- 2010-06-14 CU CUP2011000229A patent/CU24124B1/es active IP Right Grant
- 2010-06-14 DK DK19157827.7T patent/DK3517534T3/da active
- 2010-06-14 US US13/377,760 patent/US9145367B2/en active Active
- 2010-06-14 US US13/377,745 patent/US20120277230A1/en not_active Abandoned
- 2010-06-14 TR TR2019/10781T patent/TR201910781T4/tr unknown
- 2010-06-14 DK DK10728369.9T patent/DK2440546T3/da active
- 2010-06-14 BR BRPI1010768A patent/BRPI1010768C8/pt active IP Right Grant
- 2010-06-14 EP EP19157824.4A patent/EP3521283B1/en active Active
- 2010-06-14 KR KR1020177031675A patent/KR101897221B1/ko active IP Right Grant
- 2010-06-14 KR KR1020187025626A patent/KR101982463B1/ko active IP Right Grant
- 2010-06-14 CA CA2965791A patent/CA2965791C/en active Active
- 2010-06-14 BR BRPI1010772A patent/BRPI1010772B8/pt active IP Right Grant
- 2010-06-14 DK DK10728368.1T patent/DK2440545T3/da active
- 2010-06-14 KR KR1020127000915A patent/KR101789275B1/ko active IP Right Grant
- 2010-06-14 CN CN201510020820.1A patent/CN104945378B/zh active Active
- 2010-06-14 CA CA3070823A patent/CA3070823C/en active Active
- 2010-06-14 PT PT10728368T patent/PT2440545T/pt unknown
- 2010-06-14 CA CA2764026A patent/CA2764026C/en active Active
- 2010-06-14 EP EP10728368.1A patent/EP2440545B1/en active Active
- 2010-06-14 KR KR1020197004604A patent/KR102016889B1/ko active IP Right Grant
- 2010-06-14 MX MX2015016291A patent/MX364279B/es unknown
- 2010-06-14 MX MX2011013122A patent/MX340095B/es active IP Right Grant
- 2010-06-14 KR KR1020127000916A patent/KR101769616B1/ko active IP Right Grant
- 2010-06-14 FI FIEP10728369.9T patent/FI2440546T3/fi active
- 2010-06-14 EP EP10728369.9A patent/EP2440546B1/en active Active
- 2010-06-14 PT PT191578277T patent/PT3517534T/pt unknown
- 2010-06-14 CN CN202110307700.5A patent/CN113004249A/zh active Pending
- 2010-06-14 AU AU2010258214A patent/AU2010258214B2/en active Active
- 2010-06-14 FI FIEP10757474.1T patent/FI2440547T3/fi active
- 2010-06-14 EP EP10757474.1A patent/EP2440547B1/en active Active
- 2010-06-14 CN CN201710122014.4A patent/CN106905232B/zh active Active
- 2010-06-14 MX MX2015016292A patent/MX364280B/es unknown
- 2010-06-14 BR BRPI1012892A patent/BRPI1012892B8/pt active IP Right Grant
- 2010-06-14 CN CN201710158474.2A patent/CN106928194B/zh active Active
- 2010-06-14 JP JP2012514586A patent/JP5826745B2/ja active Active
- 2010-06-14 WO PCT/IB2010/052652 patent/WO2010143170A2/en active Application Filing
- 2010-06-14 PL PL10728369.9T patent/PL2440546T3/pl unknown
- 2010-06-14 MX MX2016003039A patent/MX359575B/es unknown
- 2010-06-14 WO PCT/IB2010/052650 patent/WO2010143168A2/en active Application Filing
- 2010-06-14 MX MX2011013119A patent/MX353776B/es active IP Right Grant
- 2010-06-14 EP EP19157827.7A patent/EP3517534B1/en active Active
- 2010-06-14 JP JP2012514587A patent/JP5905385B2/ja active Active
- 2010-06-14 HU HUE10757474A patent/HUE061262T2/hu unknown
- 2010-06-14 WO PCT/IB2010/052651 patent/WO2010143169A2/en active Application Filing
- 2010-06-14 CN CN201080032055.0A patent/CN102596935B/zh active Active
- 2010-06-14 CU CU2011000228A patent/CU24461B1/es unknown
- 2010-06-14 CU CUP2015000024A patent/CU24245B1/es unknown
- 2010-06-14 ES ES10728369T patent/ES2940885T3/es active Active
- 2010-06-14 FI FIEP19157827.7T patent/FI3517534T3/fi active
- 2010-06-14 MX MX2011013120A patent/MX338823B/es active IP Right Grant
- 2010-06-14 JP JP2012514585A patent/JP6041671B2/ja active Active
- 2010-06-14 ES ES10728368T patent/ES2736198T3/es active Active
- 2010-06-14 PT PT107574741T patent/PT2440547T/pt unknown
- 2010-06-14 CN CN201080032036.8A patent/CN102574835B/zh active Active
- 2010-06-14 KR KR1020177021820A patent/KR101863021B1/ko active IP Right Grant
- 2010-06-14 LT LTEPPCT/IB2010/052651T patent/LT2440547T/lt unknown
- 2010-06-14 CN CN201510021597.2A patent/CN104945379B/zh active Active
- 2010-06-14 DK DK10757474.1T patent/DK2440547T3/da active
- 2010-06-14 CN CN201910120757.7A patent/CN109776496B/zh active Active
- 2010-06-14 CU CU2011000230A patent/CU24093B1/es active IP Right Grant
- 2010-06-14 EP EP22193611.5A patent/EP4198022A1/en active Pending
- 2010-06-14 CN CN201080032045.7A patent/CN102625804B/zh active Active
- 2010-06-14 PL PL10757474.1T patent/PL2440547T3/pl unknown
- 2010-06-14 CN CN201410106644.9A patent/CN103948594B/zh active Active
- 2010-06-14 KR KR1020187025625A patent/KR101982462B1/ko active IP Right Grant
- 2010-06-14 PL PL10728368T patent/PL2440545T3/pl unknown
- 2010-06-14 BR BR122019013687A patent/BR122019013687B1/pt active IP Right Grant
- 2010-06-14 MX MX2015016293A patent/MX364989B/es unknown
- 2010-06-14 HU HUE10728368A patent/HUE045548T2/hu unknown
- 2010-06-14 KR KR1020127000914A patent/KR20120051643A/ko active Search and Examination
- 2010-06-14 MX MX2016007353A patent/MX367601B/es unknown
- 2010-06-14 PT PT107283699T patent/PT2440546T/pt unknown
- 2010-06-14 KR KR1020197004607A patent/KR102016892B1/ko active IP Right Grant
- 2010-06-14 KR KR1020197004605A patent/KR102016890B1/ko active IP Right Grant
- 2010-06-14 HR HRP20230248TT patent/HRP20230248T1/hr unknown
- 2010-06-14 AU AU2010258294A patent/AU2010258294B2/en active Active
- 2010-06-14 MX MX2015016290A patent/MX364282B/es unknown
- 2010-06-14 CA CA2764024A patent/CA2764024C/en active Active
- 2010-06-14 RU RU2011149571/04A patent/RU2567752C2/ru active
- 2010-06-14 KR KR1020197004606A patent/KR102016891B1/ko active IP Right Grant
- 2010-06-14 KR KR1020197004608A patent/KR102016893B1/ko active IP Right Grant
- 2010-06-14 CN CN201510023109.1A patent/CN104844510B/zh active Active
- 2010-06-14 US US13/377,753 patent/US20120329796A1/en not_active Abandoned
-
2011
- 2011-12-08 ZA ZA2011/09032A patent/ZA201109032B/en unknown
- 2011-12-08 ZA ZA2011/09031A patent/ZA201109031B/en unknown
-
2013
- 2013-01-11 HK HK13100514.2A patent/HK1173153A1/xx unknown
- 2013-01-17 HK HK13100736.4A patent/HK1173726A1/zh unknown
- 2013-01-17 HK HK16101060.5A patent/HK1212990A1/zh unknown
- 2013-01-17 HK HK13100731.9A patent/HK1173447A1/zh unknown
- 2013-01-17 HK HK16101080.1A patent/HK1213247A1/zh unknown
- 2013-01-17 HK HK16101079.4A patent/HK1213246A1/zh unknown
- 2013-01-17 HK HK16100761.9A patent/HK1212702A1/zh unknown
- 2013-11-22 US US14/087,762 patent/US9108919B2/en active Active
-
2014
- 2014-04-18 US US14/256,334 patent/US9908869B2/en active Active
-
2015
- 2015-01-30 HK HK15101062.4A patent/HK1200363A1/xx unknown
- 2015-04-27 JP JP2015090437A patent/JP2015155453A/ja active Pending
- 2015-06-15 JP JP2015120567A patent/JP6158250B2/ja active Active
- 2015-06-15 JP JP2015120566A patent/JP2015187150A/ja not_active Withdrawn
- 2015-06-15 JP JP2015120568A patent/JP6158251B2/ja active Active
- 2015-07-01 US US14/789,149 patent/US9637475B2/en active Active
- 2015-07-01 US US14/789,250 patent/US10017498B2/en active Active
-
2019
- 2019-10-18 JP JP2019191500A patent/JP7042245B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030207886A1 (en) * | 2000-03-17 | 2003-11-06 | Pluecker Frank | Preparation containing quinoxaline derivatives |
US20060089380A1 (en) * | 2002-07-16 | 2006-04-27 | Prana Biotechnology Ltd. | 8-Hydroxy quinoline derivatives |
Non-Patent Citations (3)
Title |
---|
Ex Parte Gerard Marguierie and Eric Malaud, PTAB 2016, Appeal 2013-004606, Application 10/587,697, copy attached, 7 pages. * |
Gordon et al. "Hutchinson-Gilford Progeria Syndrome, NCBI Bookshelf, 2003, accessed http://www.ncbi.nlm.nih.gov/books/NBK1121/ on January 26, 2016, 21 pages. * |
Loriga et al., Quinoxaline chemistry. Part 8. 2-[Anilino]-3-[Carboxy]-6(70-Substituted Quinoxalines as non classical antifolate agents. Synthesis and evaluation of in vitro anticancer, Anti-HIV and antifuncal activity, 1997, Il Farmaco, Vol 52 (8-9), Pages 531-537. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11441181B2 (en) | 2013-01-17 | 2022-09-13 | Abivax | miRNA-124 as a biomarker |
US11649211B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
US11649210B2 (en) | 2014-07-17 | 2023-05-16 | Abivax | Use of quinoline derivatives for the treatment of inflammatory diseases |
US11992499B2 (en) | 2018-12-20 | 2024-05-28 | Abivax | Quinoline derivatives for use in the treatment of inflammation diseases |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120329796A1 (en) | Compounds useful for treating premature aging and in particular progeria | |
US10975063B2 (en) | Compound, and production method thereof, and methods of treatment using the compound | |
JP6378802B2 (ja) | 早期老化、特には早老症を治療する為に有用な化合物 | |
US20220127253A1 (en) | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | |
RU2575646C2 (ru) | Соединения, пригодные для лечения преждевременного старения и, в частности, прогерии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAZI, JAMAL;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120112 TO 20120117;REEL/FRAME:028345/0102 Owner name: SOCIETE SPLICOS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAZI, JAMAL;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120112 TO 20120117;REEL/FRAME:028345/0102 Owner name: UNIVERSITE MONTPELLIER 2, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAZI, JAMAL;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120112 TO 20120117;REEL/FRAME:028345/0102 Owner name: INSTITUT CURIE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAZI, JAMAL;MAHUTEAU, FLORENCE;NAJMAN, ROMAIN;AND OTHERS;SIGNING DATES FROM 20120112 TO 20120117;REEL/FRAME:028345/0102 |
|
AS | Assignment |
Owner name: ABIVAX, FRANCE Free format text: MERGER;ASSIGNOR:SPLICOS;REEL/FRAME:034759/0705 Effective date: 20140919 |
|
AS | Assignment |
Owner name: UNIVERSITE DE MONTPELLIER, FRANCE Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:UNIVERSITE DE MONTPELLIER 2;UNIVERSITE MONTPELLIER 2;REEL/FRAME:037179/0237 Effective date: 20150101 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |